List of Therapeutic Companies with Phase 4 Active Clinical Trial - 348

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.htm

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

Nasal breathing is a very important function of human life and any obstruction in the nasal airway also known as a congested or blocked nose, can dramatically impact the quality of life.The VIVAER treatment, performed in a doctor’s office, is a non-invasive procedure without any incisions. The patient'snasal valve area is gently reshaped using low-temperature radiofrequency energy with lasting results.

Affluent Medical est un nouvel acteur français de la medtech ayant pour ambition de devenir un des leaders européens dans les domaines cardiovasculaires et urologiques. Affluent Medical développe des implants innovants mini-invasifs de nouvelle génération pour restaurer des fonctions physiologiques essentielles dans ces domaines : - Kardiozis vise à prévenir les endofuites et les risques de récidive de l'anévrisme de l'aorte abdominale permettant aux patients de vivre plus sereinement face à un risque de rupture imprévisible ; - Kalios et Epygon visent à offrir des traitements chirurgicaux plus physiologiques pour la réparation ou le remplacement de la valve mitrale du cœur. Kalios permet de traiter les fuites résiduelles post-opératoire et l'insuffisance mitrale récurrente sans avoir à réopérer les patients. Epygon est aujourd'hui la seule valve transcathéter en développement permettant de restaurer les flux sanguins naturels et de sauvegarder le ventricule gauche. - Enfin, Artus est le premier sphincter artificiel activable électroniquement pour traiter l'incontinence urinaire d'effort des hommes et des femmes. Nos avancées technologies permettent d'offrir des dispositifs médicaux qui respectent davantage la physiologie du corps humain. Nos implants sont mis en place grâce à un chirurgie mini-invasive et visent à limiter les risques de récidive précoce ou tardif de la maladie. Les trois prothèses innovantes et la technologie d'Affluent Medical sont en phase sont préclinique ou clinique.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world. Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, as well as local and regional operations in countries around the world. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day.

Alkermes seeks to develop innovative medicines that help address the unmet needs and challenges of people living with debilitating diseases. As a fully-integrated, global biopharmaceutical company, Alkermes applies its scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

Alleviant Medical is a medical device company developing next-generation therapies for heart failure.

Allievex is committed to developing first- and best-in-class therapies to benefit children with rare and devastating neurological diseases. Using intracerebroventricular administration of enzyme replacement therapy, we safely deliver our therapies where they’re needed most—to the cells of the central nervous system. Data from ongoing clinical trials for our first drug, tralesinidase alfa, provide preliminary, promising results for Sanfilippo syndrome type B patients. These findings offer exponential hope: an effective treatment for one rare pediatric neurological disease can uncover the keys to countless more.

Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally restore normal physiological function in women suffering with mixed urinary incontinence. The company's first therapy, Amber UI, is an intelligent closed-loop bioelectrical therapy for urge and mixed urinary incontinence. The startup has also acquired Bioinduction, a fellow U.K.-based company and the maker of the Picostim DyNeuMo platform.

American Gene Technologies® International Inc. (AGT™) is a private biotechnology company pursuing cures and treatments for infectious diseases, cancers, and monogenic disorders. AGT™'s emerging gene and cell therapeutics programs are designed to: ✅ Create immunotherapy for HIV disease with gene-modified T cells ✅ Activate innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology ✅ Treat PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation ✅ Advance clinically to provide human proof of concept For over a decade, AGT™ has developed, tested, and banked thousands of lentiviral vectors that can be adapted to the specific needs of new target diseases. AGT™ has developed gene therapy for diseases using this rapid gene delivery platform. GENE THERAPIES AGT™’s platform allows it to pursue clinical “cures” for complex diseases. The company has developed patent-protected gene therapeutics that are breakthroughs in medicine. *** See our extensive award winning patents on our website *** HIV/AIDS Immunotherapy for HIV disease with gene-modified T cells IMMUNO-ONCOLOGY Activates innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology PHENYLKETONURIA (PKU) Treats PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation AGT™'s Core Objectives ✔️ Leverage our lentivirus platform to create highly-effective targeted genetic medicines ✔️ Create solutions for patients across a spectrum of infectious diseases, cancers and inherited disorders ✔️ Collaborate with leading medical researchers from around the globe To learn more and get in touch with American Gene Technologies® Inc., contact us today at https://www.americangene.com/contact-us/

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2018 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. We are redefining interventional therapy for severely calcified lesions with our Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device. To learn more about pulsatile intravascular lithotripsy, visit www.avspulse.com.

Amryt Pharma was acquired by Chiesi Farmaceutici S.p.A. (“Chiesi”) April 12, 2023. Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

Health is the level of functional or metabolic efficiency of a living organism. In humans it is the ability of individuals or communities to adapt and self-manage when facing physical, mental or social challenges.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Zhifei is a high-tech biological enterprise integrating the R&D, production, distribution as well as import & export to mainly produce vaccines for human use.

Anteris Technologies is a structural heart company focused on developing innovative solutions to the biggest challenges facing aortic stenosis patients and their physicians. Our DurAVR™ Transcatheter Heart Valve (THV) System is designed for younger patients who need a heart valve that will last their lifetime. DurAVR™ THV is a unique, single-piece valve and its first-in-class biomimetic design replicates the normal blood flow of a healthy human aortic valve. | $AVR | ASX: AVR | #DurAVR #ADAPT #structuralheart #TAVR #TAVI #cardiology

Previously known as AOP Orphan, AOP Health is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families as well as also the doctors and care professionals treating them. Needs. Science. Trust. The international healthcare group focuses on research, development and global sales of innovative treatment solutions. AOP Health believes it has a responsibility to make innovative integrated therapies and disease-management solutions available long term to as many patients as possible who suffer from rare diseases or require critical care.

Applied Biologics is a fully-integrated life sciences company providing research, product development, manufacturing and distribution of medical technologies. Since 2010, Applied Biologics has been dedicated to providing innovative biologic solutions to deliver optimal patient outcomes. The entire Applied Biologics team is dedicated to each other and the company's success. The executive team, medical advisory board, scientific advisory board, researchers, product development team, manufacturing technicians, distribution team, sales representatives, support team, reimbursement department and administrative staff are professionals and leaders in their fields. Together, we continue to strive for excellence and being a leader in delivering biological solutions to treat a growing list of medical indications.

Aptitude Vision is a biotechnology company that specializes in developing next-generation synthetic biomolecules for treating vision-threatening diseases by simultaneously targeting multiple pathological processes.

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Community Guidelines: https://rb.gy/07ltg3

Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan.

AROG Pharmaceuticals, Inc. was formed to expedite and streamline the transition of early stage molecules into areas of unmet therapeutic needs. We are committed to scientifically validated drug development in collaboration with like-minded investigators and institutions.

Arsenal Medical is a clinical-stage company that develops biomaterials to solve challenging and underserved medical problems. It was founded by serial entrepreneur-investor Carmichael Roberts and academic luminaries Robert Langer and George Whitesides, who shared a vision for how materials can transform medicine. The company’s foundational product, ResQFoam, is a life-saving intervention that addresses non-compressible intra-abdominal hemorrhage in trauma patients. It has been designated a breakthrough device by the FDA.

Was SilverBack Therapeutics, merged with ARS Pharma in 2023 ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including food, medications, and insect bites. The company was founded in 2015 and is based in San Diego, California.

Artiria Medical is a Swiss neurovascular company that empowers catheters and guidewires, developing cutting-edge technologies to revolutionize the limits of neurointerventional procedures. Their medical device offers navigation in brain arteries and stroke treatment, allowing for the treatment of vascular diseases. The company has secured FDA clearance for their real-time, deflectable guidewire and has received funding to advance stroke treatment technology in Europe and the US.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.

Focusing on developing the best nucleic acid amplification and detection technologies for clinical molecular diagnostics - COVID-19 (FDA EUA Approved), Non Invasive Prenatal Test, HPV Detection, STI, NGS Cancer Panel (Lung, Breast, Colorectal), and many more.

Atreon Orthopedics is a tissue regeneration company powered by breakthrough regenerative technology and renowned scientific expertise. Tendon and ligament injuries affect ten million people yearly, spanning all lifestyles and demographics. Atreon is committed to dramatically improving healing and long-term outcomes for patients encountering these soft-tissue injuries. ROTIUM®, our initial product for rotator cuff repair, is a bioresorbable wick designed as a scaffold to harness and hold biologically active substances at the repair site providing a pro-healing environment that promotes healthy tissue and native tissue regeneration. Recently published human and animal studies and over 10,000 cases have shown a safe and effective solution to improving biology, restoring function, and improving rotator cuff success rates.

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE®+ and cryoSPHERE MAX™ probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.

ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies and financial support from the Dutch government. The collaboration between the clinical, biomechanical and polymer experts has been instrumental in the development of our Meniscus Prosthesis. Artimis® will be the first anatomically shaped polymer based meniscus implant. Please note, Artimis® is an investigational device in development and is not available for clinical use the coming years. More information can be found on www.atromedical.com

AVITA Medical (NASDAQ: RCEL, ASX:AVH) is a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a Biosynthetic Wound Matrix, in the United States.

Axogen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen’s comprehensive portfolio of products focuses on helping patients touch, run, feel, kiss, smile and hug—some of the many things healthy peripheral nerves allow us to do.

Axolotl Biologix, located in Arizona is a dynamic biotech company focused on developing and producing human biologics and biological-related products to reduce inflammation and foster regeneration for many conditions that affect patients, including orthopedic, wound care, cosmetic and more. Axolotl is currently negotiating partnerships with universities and research hospitals to find ways to improve current technologies and procedures to improve patients’ quality of life.

Axon Therapies is addressing a root cause of heart failure with their frontline therapy by selectively ablating the neural pathway carrying information from the chronically hyperactive sympathetic nervous system (SNS) in order to restore volume balance, stop disease progression and improve symptoms

Our Mission: For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines

Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of patients with underserved conditions. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients.

We're a leading global eye health organization that is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, we have a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries.

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Our products and services are designed to benefit people and improve their quality of life. At the same time, we aim to create value through innovation, growth and high earning power. Our products help address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. In line with our mission “Bayer: Science For A Better Life,” we aim to improve people’s quality of life by preventing, alleviating or curing diseases. We also help provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. For these endeavors, we focus on developing and successfully commercializing innovative products and solutions based on scientific knowledge.

B. Braun is one of the world's leading medical technology companies. With over 65,000 employees, the family-owned company is a true partner, developing smart solutions and setting standards to drive advancements in health care. In 2022, the B. Braun Group generated sales of € 8.5 billion. You want to protect and improve the health of people around the world? Then you need a work environment that makes it easy for you to give your best. We bring together people in a collaborative culture. We encourage them to be open-minded, learn from each other and create new solutions together. In a time of rapid technological change, we constantly strive to enhance the solutions we provide. This is why we promote innovative ways of thinking and accountability. Imprint: https://www.bbraun.com/en/imprint.html Privacy Policy: https://www.bbraun.com/en/privacy-policy.html

BioCytics via the Human Applications Lab is focused on bringing personalized oncology treatments to the market. BioCytics has an ongoing IRB-approved clinical trial (BioCytics 0001; NCT00571389) that allows for the collection and study of blood and tissue samples from consenting cancer patients. We are incubated within Carolina BioOncology - a preferred cancer treatment and Phase I drug testing facility. BioCytics was founded by Dr. John Powderly, MD, medical board certified oncologist and a certified physician investigator (CPI), who is also president of Carolina BioOncology Institute (CBOI).

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.

BioPoly® was established to provide a treatment option for painful cartilage lesions between the extremes of biological solutions and total joint replacement. Utilizing a patented material that is self-lubricating for improved wear properties (via a biological enhancement with Hyaluronic Acid) the BioPoly® RS devices are uniquely designed to replace only the damaged cartilage. Therefore, patients can quickly recover and return to pain-free, active lifestyles. BioPoly® RS devices are currently available for femoral condyle, trochlear facets, trochlear groove, patella, and humeral head applications. Patients out to >10 years have experienced a significant reduction in pain and have shown improved quality of life. Additional orthopedic applications are currently in development. BioPoly® serves healthcare professionals and their patients throughout the world from our headquarters in Fort Wayne, Indiana, USA.

Bio-Thera Solutions is a clinical-stage pharmaceutical company focused on biologic therapeutics. Bio-Thera is developing a pipeline on innovative enhanced monoclonal antibodies and antibody-drug conjugates for the treatment of a broad range of cancers and other diseases as well as a pipeline of biosimilars in the autoimmune and oncology therapeutic areas. The company is headquartered in Guangzhou, China.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology.

Blueprint Medicines Corporation, a precision therapy company, develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

BONESUPPORT AB is a Scandinavian orthobiologics company based in Lund, Sweden, specializing in advanced bone graft solutions. Founded in 1999, the company develops and commercializes bioceramic products aimed at managing bone injuries. Its flagship product, CERAMENT®, is an injectable bioceramic material designed for bone void filling and infection management, featuring osteoconductive properties and drug-eluting capabilities for localized antibiotic delivery. The company operates globally, achieving net sales of SEK 899 million in 2024, with significant growth in both North America and Europe. BONESUPPORT focuses on direct commercialization in key markets and partnerships for global distribution. The leadership team includes experienced executives in business administration and orthobiologics, with a strong emphasis on clinical validation and innovative solutions for orthopedic surgeons, trauma centers, and hospitals.

Boryung is a healthcare investment company founded in 1957 and headquartered in Seoul, South Korea. Following the company’s mission to become an indispensable contributor to human health, we have expanded our business portfolio to the space healthcare industry. Recognizing space as a new growth realm, we acknowledge the increasing number of individuals anticipated to embark on extended space missions, highlighting the importance of ensuring human survival in the hostile space environment. Hence, Boryung believes there will be substantial opportunities to foster new technologies and meet the emerging needs in this field.

BostonGene is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Britannia Pharmaceuticals, part of the STADA Arzneimittel AG group of companies, is a UK based pharmaceutical company specialising in the neurology market. Britannia focuses on innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson’s disease. We are highly committed to improving the quality of life for People with Parkinson's disease.

Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for chronic and acute pain. Their Neural Ice™ has the potential for long-lasting pain control from one injection, intended to eradicate the pain of pain.

Cadence Neuroscience is developing a fundamentally new approach to neuromodulation, starting with a therapy to treate severe epilepsy.

Cagent Vascular (Wayne, PA) has developed and commercialized its novel angioplasty balloon with Serration Technology to treat blocked arteries in the leg or Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). The Serranator PTA Serration Balloon Catheter is the first and only angioplasty balloon with serration technology

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

CanSino Biologics Inc. (CanSinoBIO, SHSE: 688185, HKEX:06185) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting-edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide. Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with 17 vaccines preventing 12 diseases, including approved vaccines for Ebola virus disease (Ad5-EBOV), COVID-19 (Ad5-nCoV, trade name: Convidecia), and meningitis (MCV2, trade name: Menphecia). CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) in March 2019. A year later, CanSinoBIO has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates. Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed five key platform technologies, including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant technology, mRNA technology as well as formulation and delivery technology.

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

Catalyst is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases.

We are a global team on a mission to solve the persistent problem of migraine through advanced therapeutic innovations. Our name, CEFALY (pronounced sef‑a‑LEE), is derived from céphalée, the French word for headache, and cephalic, a medical term that means "related to the head." Since 2008, we've continued to test and improve our proprietary device, CEFALY DUAL, to offer people with migraine a safe and effective, drug-free treatment. While the causes of migraine are not completely understood, current research shows that the largest and most complex cranial nerve, the trigeminal nerve, is heavily involved in the sensation of migraine headache pain. CEFALY DUAL has been specifically engineered to modify pain sensation in the trigeminal nerve through its ophthalmic branch, which runs under the skin of the forehead.

CellOrigin Biotech has a long term focus on iPSC-derived innate immune cells and its applications in new cancer immune cells. Dr. Jin Zhang, the scientific co-founder of CellOrigin used to be trained as a research fellow at the Boston Children’s Hospital and Harvard Medical School. His team worked closely with clinicians at the First Affiliated Hospital of Zhejiang University and for the first time reported the induced pluripotent stem cell or iPSC-derived CAR-macrophages (CAR-iMac), and its applications in cancer immunotherapies. As for now, CellOrigin Biotech holds its proprietary technologies for iPSC-derived CAR-Macrophage. With this platform, they are collaborating with research groups in genome engineering and synthetic biology at Harvard and MIT to fully unleash the potential of iPSC-derived immune cells, which are highly editable, expandable and clonal. Eventually, they would like to achieve a goal of bring more effective, universal and safe immune cell products to cancer patients, especially for those with solid tumors. The investigator initiated trials has been initiated at the First Hospital of Zhejiang University. The core proprietary technology platform and the core patents including the engineered macrophages from pluripotent stem cells has been authorized and is in the process of entering the US, Australia, South Africa, etc.

Celltrion is a leading biopharmaceutical company that specializes in research, development and manufacturing of innovative therapeutics. We are committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. We have been at the forefront of biotherapeutic development uncovering new ways of targeting the drivers of disease by creating next-generation biologics and small molecule products. For additional information on our guidelines, please visit: http://tinyurl.com/bdh9bxs9

Cerapedics is a global, commercial-stage orthopedics company that aspires to redefine the standard of care for bone repair by healing bones faster and at higher rates, without compromising safety, so that patients can live their healthiest lives. Bone grafts, including Cerapedics’ products, are used in over four million annual spine, orthopedics, trauma and interventional procedures world-wide. Cerapedics’ product, i-FACTOR®, is FDA approved for single-level cervical spinal fusions in the United States. Cerapedics’ next-generation product is currently being evaluated for use in lumbar interbody fusion through ASPIRE, a pivotal IDE study, and has been granted a Breakthrough Device Designation by the FDA. Cerapedics is headquartered in Westminster, CO.

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.

CereVasc, Inc. is a clinical-stage, medical device company developing novel treatments for neurological diseases. The company is focused on developing the eShunt™ System for the treatment of patients with hydrocephalus. CereVasc aims to improve patient outcomes and redefine the treatment of communicating hydrocephalus through its innovative medical devices.

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Channel Medystems develops a cryotherapy device for the treatment of gynecology disorders.

Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making.  As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

CivaTech Oncology® designs innovative products that bring meaningful improvements to low dose rate brachytherapy. The CivaString® and CivaSheet™ can substantially reduce procedure time, provide homogeneous dose distribution and minimize trauma. Customizable CivaTech products ensure that radiation oncologists can deliver individualized, targeted therapy to treat cancer. http://www.civatechoncology.com/

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions. The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.

Concept Medical Inc. is a Research-oriented organization. It is into the development of a novel drug-eluting balloon catheter (DEB) using the latest Nano Technology. Aim of CMI is to develop innovative and revolutionary medical devices for the treatment of Cardiovascular Diseases. Concept Medical Inc. was incorporated on June 2008 in Cleveland OH. Later on, the company moved to San Jose, California. Currently, the company has a Business Development office with its Main Research Unit located at Surat, India. Concept Medical Inc. has set up a full-fledged research center which is involved in the development of Nanocarrier based drug delivery technology. Its team of Scientists and Engineers hold International Patents on research. Concept Medical Research Pvt. Ltd. has featured on Indian Government's list of top ten companies in the Pharmaceutical sector for its research in Medical Device technology. Our core development areas and offerings include drug delivery technologies comprising of various types of coatings, nanoparticles, and nanocarrier delivery systems, and coatings that have pro healing properties, and biocompatibility capabilities. Our strategy is to build on our strong technical leadership in the field of Nano carrier-based drug delivery and products, visioning to strengthen our position as an innovative and resourceful product development partner to the Medical Device industry.

Conformal Medical develops medical devices to prevent stroke in patients with non-valvular atrial fibrillation. The company's proprietary technology will help left atrial appendage closure meet its true potential.

Patented, Drug-Free, Faster, and More Effective Treatment for Vaginal Infections. Powered by Project Medtech.

Cordis is a medical devices company that specializes in cardiology equipment and healthcare technology.

As a leader in orthopaedic innovation, Corin has pioneered a number of landmark developments since its foundation and is proud to have been able to improve the quality of life of thousands of patients around the world through these groundbreaking products. The company's talented and dedicated teams share a common commitment to deliver quality orthopaedic products and services to patients, surgeons and healthcare providers which exceed expectations and positively impact lives. With an increasingly active and demanding patient population, the need to provide state of the art conservative treatment pathways, in addition to more traditional interventions, has never been more important. Corin's product portfolio is designed to provide each patient with the optimal solution, utilising some of the most advanced technologies available in the world to enhance implant longevity and performance.

Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world's largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

Corvia Medical, Inc. is revolutionizing the treatment of heart failure with a novel transcatheter structural heart device. Founded in 2009 and headquartered in Tewksbury, MA, Corvia Medical is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. The Corvia® Atrial Shunt is the world’s first transcatheter device approved by the European Union to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction. Privately held, the company is backed by Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures, Edward Lifesciences and an undisclosed strategic investor. In the United States, the Corvia Atrial Shunt System is an investigational device and not available for commercial distribution or sale.

CorWave is a French company developing innovative cardiac assist devices. CorWave's wave membrane pump is a breakthrough technology that differs from today's commercially available left ventricular assist devices (LVADs) by its physiological operation, designed to mimic a pulse and blood flow rates similar to those of a healthy heart. Ultimately, CorWave's membrane pump technology is expected to reduce the complications associated with current devices and improve the management of heart failure patients. A member of the French Tech 120, CorWave was founded in 2012 by start-up studio MD Start and is funded by renowned investors including Bpifrance, Exor Ventures, EIC Fund, Financière Arbevel, M&L Healthcare, Novo Holdings, Seventure Partners, Sofinnova Partners, Ysios Capital and Vlerick Group. The company has secured over €80 million in equity and employs over seventy people.

At Creo Medical we are dedicated to improving patient outcomes by bringing advanced energy to therapeutic endoscopy. Our integrated electrosurgery unit delivers Bipolar Radiofrequency for precise dissection and resection and Microwave energy for controlled ablation and coagulation. This technology sets a new standard for Endoscopic Submucosal Dissection with our new Speedboat RS2 instrument: the Bipolar Radiofrequency cut allows precise dissection and the microwave coagulation provides controlled haemostasis while the protective hull reduces the risk of muscle damage and the integrated injection needle helps to maintain submucosal lift without instrument changes.

Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company's award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company's other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

CryoTherapeutics is a company that focuses on developing cryotherapy systems for the treatment of heart attacks in Europe and the USA.

CSL Behring is a biopharmaceutical company that manufactures plasma-derived and recombinant therapeutic products.COVID-19: CSL says it is working on a plasma-based therapy for patients with more severe forms of COVID-19.The company is part of the CSL family of companies. The parent company, CSL Limited is based in Melbourne, Australia, employs more than 30,000 people, and delivers its life-saving therapies to people in more than 100 countries.

CSPC Pharmaceutical Group Limited is a leading pharmaceutical company based in Shijiazhuang, Hebei, China. The company focuses on the research, development, manufacture, and sale of a wide range of pharmaceutical products. With a strong emphasis on innovation, CSPC has a robust research and development team of over 2,000 members, including many with advanced degrees and international experience. Their R&D efforts span multiple locations, including Shijiazhuang, Shanghai, Beijing, and the United States. CSPC offers a diverse array of pharmaceutical products, including finished drugs like capsules, tablets, and injections, as well as bulk drugs such as active pharmaceutical ingredients. Their product range addresses various therapeutic areas, including oncology, cardiovascular health, respiratory conditions, anti-infectives, and diabetes management. The company also has an extensive pipeline of over 300 projects focused on innovative drug development, highlighting its commitment to advancing healthcare solutions. CSPC's products are available in multiple regions, including the Americas, Europe, and Asia, serving a broad customer base in the healthcare sector.

Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes FDA-approved branded prescription products. We are the largest publicly listed biopharmaceutical company founded and headquartered in Nashville, Tennessee. Nashville has become a leading center for health care in the United States, with over 300 companies headquartered here, and working in that industry. Cumberland is collaborating with Vanderbilt University and the Vanderbilt University Medical Center through a growing number of research and development programs. We are devoted to improving the quality of patient care and addressing poorly met medical needs. With a focus on underserved niche markets, we deliver products that serve patients in the U.S. market as well as internationally through select partnerships. Our commercial organization supports our branded products in the U.S., while our development team is working on new medicines for the future. Our primary focus is to improve patient care by providing differentiated products that offer clear advantages over other treatments. We also strive to deliver solutions that may help reduce costs for healthcare providers and, ultimately, patients.

Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation. We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have. As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing. Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians. Our Promise We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.

CVRx is a commercial stage, public (NASDAQ: CVRX) medical devices company located in Minneapolis, Minnesota. The company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim™ triggers carotid baroreceptors - the body's own natural blood flow regulation system - which signals the brain to regulate cardiovascular function. Patient Stories on CVRx: The accounts and quotes of patients are genuine and documented. These stories represent a unique individual experience and does not provide any indication, guide, warranty or guarantee as to the response other people may have to CVRx technologies. Barostim is a prescriptive device. For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. CytoSorbents is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorbents has multiple active, clinical trials ongoing, including two pivotal randomized, controlled trials in the United States designed to support eventual FDA marketing approval for antithrombotic removal during cardiothoracic surgery using the DrugSorb™-ATR Antithrombotic Removal System.

At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.us. See our community guidelines here: https://bit.ly/4fLkZS8

DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

Medical device sales/distribution organizations needed for a non-narcotic chronic pain treatment solution develop by DyAnsys Inc. Be a part of a billion-dollar market. This innovative solution has tremendous growth potential with the current focus on reducing the use of narcotics for pain treatment. DyAnsys Inc. has been growing rapidly and needs to expand its coverage of the U.S. market. Distributors who are already working in the pain management field and have a base of pain management clients are preferred. Successful candidates should: • Have been in the medical device sales and distribution business for at least five years. • Have a sales force or access to 1099 reps to assure full territory coverage. • Be able to focus on DyAnsys products to grow the business rapidly. To learn more: Call 1-888-950-4321 or e-mail new.distributor@dyansys.com DyAnsys Inc. is a global company, headquartered in the Silicon Valley (California, USA), and is led by a worldwide team of professionals drawn from the medical, mathematical and IT fields who are working hard to make DyAnsys a worldwide leader in providing advanced medical diagnostic and monitoring systems to clinicians in individual practices and hospitals. By using sophisticated mathematical analysis of the ECG and other electrical signals, DyAnsys applications focus on chronic and acute pain, anesthesia, diabetes, and fetal heart monitoring.

Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.

EIG's mission is to develop highly accurate and non-invasive multi-omic molecular testing solutions for complex diseases like cancer. The company has developed a Multi-omic Integration Platform that combines detection of DNA, RNA, protein and metabolite targets into a single assay. This breakthrough approach transforms the field of molecular diagnostics by offering unparalleled accuracy with comprehensive insights for early disease detection. www.earlyisgood.com.

Echosens is a healthcare technology company that specializes in non-invasive diagnostic tools for assessing liver health.

Advancing regenerative medicine through the development of a natural biomaterial that restores mother nature’s template to treat disease and injury. ECM scaffolds, in solid form, have been successfully used in more than 10 million human patients to repair a variety of body systems such as musculoskeletal tissues, cardiovascular structures, and non-healing skin wounds, among others. These products have all received FDA clearance. ECM Therapeutics'​ patented ECM hydrogel technology allows for expanded, less invasive applications in multiple disease areas. The first clinical product, EsophaGel, treats Barrett’s esophagus, a precancerous condition that currently has no effective therapy.

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners.

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in San Rafael, California International Offices: Ekso Bionics Europe GmbH Friesenweg 20 Hamburg, 22763 Germany Tel: +49 40 800 4049 20

In 2005, we were founded on a unified belief that neuromodulation could be used in novel ways to help patients break free from treatments they aren’t happy with. Because different modalities of neuromodulation had previously proven to be effective and safe, we recognized an opportunity to be the leader in this new frontier of medicine and took it head on. Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop safe and clinically backed treatments. Bringing new treatments to market will help improve patients'​ treatment options and lives.

Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. The company’s aGal (RPV-001) program to treat Fabry disease has completed a Phase 1b clinical study with promising results. All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

ElmediX is an oncology company committed to develop innovative medical technologies that can boost conventional anticancer therapies through Hyperthermal Therapy. Our main goal is to increase patient quality of life and survival. Our HyperTherm platform is a semi-automated, real-time system which offers accurate, highly-reliable and sensitive temperature control of the patient during treatment. A software-based technology is responsible for an accurate thermal mapping of the patient’s body; this guarantees that the temperature remains within a safe range during treatment. We have an ongoing clinical trial investigating the safety of thermal therapy in advanced solid cancer patients. The trial focuses on patients who do not respond to current standard therapies, patients with cancer types not adequately addressed by available therapies or patients that refuse standard of care treatment. For more information about the clinical trial, please use the following link: https://clinicaltrials.gov/ct2/show/NCT04467593?cond=Pancreatic+Cancer&cntry=BE&draw=2&rank=5 For more information about ElmediX, please check our website: www.elmedix.com

At Elutia we’re pioneering the future of patient care. Our proprietary drug-eluting biomaterial platforms stand at the forefront of medical innovation.

Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma. Several years of research in Nielsen lab at Chalmers University of Technology in Gothenburg, Sweden led to the founding of Elypta in May 2017 by Francesco Gatto and Jens Nielsen.

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Endogenex, in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). Endogenex's innovations focus on resetting the body's metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function. Through the development of the ReCET System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in treatment options for people living with T2D, helping patients regain control of their blood glucose levels and slow disease progression. Endogenex is a privately held, clinical-stage company based in Minneapolis, MN.

At Endo, our far-reaching vision is simple: to help everyone we serve live their best life. As a specialty pharmaceutical company, we’re motivated by a strong sense of purpose to find better ways to meet unique medical needs. Our global team of passionate employees understands the importance of their work. We’re dedicated to supporting one another as we connect with communities and foster partnerships that elevate quality-of-life and bring the best treatments forward. Our uncompromising commitment results in the delivery of life-enhancing therapies. From intelligent product selection to commercialization, we strive to make a meaningful, tangible impact to help everyone live their best life. Endo has global headquarters in Malvern, Pennsylvania. Community Guidelines: 1. Be respectful. Everyone who visits our page should feel comfortable and respected. 2. If we see a comment that violates anything in the following list, it may be removed. • Comments that use profanity; personally attack or bully another individual; or are off-topic, misleading, factually inaccurate, political, spam, defamatory, discriminatory or promotional. • Comments that are excessively repetitive and/or disruptive to the community. • Comments that promote illegal activity, use copyrights or trademarks or are related to an ongoing legal matter. • Comments that appear to be medical advice. We reserve the right to remove a reply for any reason at any time. 3. Adverse Event Reporting: If we see a post about an adverse event, an Endo representative will need to contact you to find out more information to comply with regulatory guidelines. If you experience a side effect while using an Endo product, please consult your physician or pharmacist immediately. You may also report to the FDA at fda.gov/medwatch or 800-FDA-1088. Replies from other users do not necessarily reflect the views of Endo. We do not endorse content added by other users.

The NEXUS® Aortic Arch Stent Graft System by Endospan is the only CE-approved off-the-shelf branched endovascular aortic arch system. Indicated for wide range of aortic pathologies, including arch aneurysms, thoracic dissections, and PAU, NEXUS® is designed to overcome the specific challenges of the aortic arch anatomy. The NEXUS® "Dock and Lock" modular system provides stable and secured anatomical anchoring and atraumatic sealing in a wide range of anatomies. Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan's NEXUS® Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website at www.endospan.com.

Endovascular Engineering, Inc. ("E2"), is a mission driven, venture-backed company focusing on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism.

Enspire DBS Therapy, in partnership with Cleveland Clinic and Boston Scientific, is developing a proprietary deep brain stimulation (DBS) therapy to restore motor function for stroke survivors living with disability. Enspire is currently sponsoring EDEN, a Phase I clinical trial of DBS therapy for stroke recovery.

Entrinsic Bioscience is a biotechnology company that specializes in developing functional ingredients and Active Pharmaceutical Ingredients (APIs) through a proprietary platform centered on amino acid combinations. The company utilizes a biomapping and electrophysiology platform to identify and patent specific amino acid combinations that influence protein regulation and cell signaling. This technology has its origins in research conducted with NASA, aimed at addressing gastrointestinal damage from ionizing radiation during deep space missions. The company offers a range of applications, including products for pulmonary health, digestive health, immune regulation, metabolism, hydration, and skin health. One of its notable products is enterade IBS-D, a non-prescription medical food designed to manage symptoms of IBS-D. Entrinsic collaborates with healthcare providers, academic institutions, and global partners to commercialize its formulations, focusing on science-backed, plant-based solutions that enhance health outcomes.

We are ESTEVE, a global pharmaceutical company with one defined mission: improving lives. Founded in 1929 and headquartered in Barcelona, we have a strong international footprint, with affiliates across Spain, Portugal, Italy, Germany, France, the UK, and the USA. As a leader in speciality pharmaceuticals, we focus on creating highly specialized treatments that address significant unmet medical needs. Our expertise extends to Contract Manufacturing, where we produce Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, and China. Driven by our core values—people matter, transparency, and accountability—we’re committed to innovation, quality, and making a meaningful difference in healthcare. Because we care not only about what we do, but also about how we do it. #ESTEVE #AdvancingHealthTogether #Makeitsustainable #Pharmaceuticals #Innovation #SpecialtyPharma #APIs

Eusol Biotech was founded in March 2005 in Taipei, Taiwan. The company is involved in the R&D and GMP process development of recombinant human acid fibroblast.

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Exero Medical's mission is to empower health care providers with high-quality, actionable post-operative tissue healing data that can save lives, improve prognosis, and reduce cost of care. The company's flagship product, the xBar system, has been granted Breakthrough Device Designation by the FDA.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

We exist because we want to positively impact the lives of the 1 Billion people living with neurological disorders. We are a team of doctors and doers that are on a mission to develop and deploy our AI-based clinical decision support tool that analyzes passive eye-movements to give clinicians the data they need to effectively manage the neurological health of their patients...starting with Epilepsy.

Overactive bladder (OAB) affects over 15 million women in the US. The sudden, urgent desire to pass urine greatly limits quality of life. Current treatments are not optimal, requiring frequent, time-consuming office visits, awkward vaginal probes, medications with potential side effects or surgery. Those suffering with OAB often consider the therapies too cumbersome and forgo treatment, opting instead to place limits on their life to accommodate the symptoms. Neuromodulation for OAB involving electrical stimulation of the sacral nerve is a proven and established therapy. However, despite being commercially available for over a decade only a small fraction of indicated patients have been treated. The cost and invasiveness of the surgery are often cited as concerns by prospective recipients. FemPulse has developed a novel, wearable medical device designed to deliver neuromodulation therapy directly to the nerves that regulate bladder function, without the need for surgical implant. The small device is easily placed by the patient herself and controlled with a smartphone app. The company is currently conducting clinical evaluations in the United States.

Field Medical, Inc. is a medical technology company based in Cardiff-by-the-Sea, California, focused on developing advanced pulsed field ablation (PFA) systems for treating cardiac arrhythmias. Founded in 2022 by Dr. Steven Mickelsen, a pioneer in PFA technology, the company is dedicated to improving catheter-based ablation therapies to meet clinical needs. Field Medical has made significant progress, moving from preclinical development to clinical trials, and has secured substantial funding to support its initiatives. The company's flagship product, the FieldForce Ablation System, includes the FieldForce Catheter and FieldForce Generator. The catheter is designed for ventricular arrhythmias, providing precise lesion formation with real-time force feedback. The generator utilizes proprietary FieldBending™ technology to deliver high-intensity pulsed electric fields, targeting arrhythmias while minimizing damage to surrounding tissue. Field Medical's clinical programs focus on ventricular tachycardia and atrial fibrillation, with promising early results from pilot studies and ongoing first-in-human trials. The company aims to establish PFA as the standard of care in cardiac ablation, leveraging its innovative technology and strategic funding to enhance its market presence.

Our Vision: To revolutionize the structural heart market with new material, design and manufacturing technology expanding patient access, improving product performance and significantly reducing costs.

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit us at www.FoundationMedicine.com or follow @FoundationATCG on Twitter. Community Guidelines: bit.ly/FMICommunityGuidelines

Fractyl Health is a leader in creating innovative therapies to address the root cause of type 2 diabetes. We were founded based on groundbreaking research and biological insights showing the key role of the intestine in metabolic control. Our therapies are uniquely designed to target and control this controller for the treatment of metabolic disease. Our lead program, Revita DMR, is a first-in-class procedural therapy that is now in late-stage clinical trials for the treatment of type 2 diabetes. Our team is made up of passionate innovators at the intersection of biology and technology, working to deliver better real-world outcomes for people with metabolic disease.

Freya™ is a clinical-stage company taking an innovative approach to women’s health, with microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of reproductive system diseases uniquely afflicting women.

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer.

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.a r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or patientinfo@gene.com. Community Guidelines: 1. We want to foster positive conversation and diverse community around the issues we are passionate about. To that end, we remove profanity, content that contains credible threats or hate speech, content that is aimed at private individuals, personal information meant to harass someone, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy's lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.

We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinaryTM experience. Established in 1999, we are headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com. Disclaimer: http://bit.ly/GENDisclaimer

Based in Sudbury, MA., Gentuity is a commercial-stage medical technology firm dedicated to developing next-generation intravascular imaging devices capitalizing on today's best-in-class technologies. Gentuity was founded on the principles of advancing patient care, improving outcomes, and expanding the utility of intravascular procedural guidance tools in the realm of cardiovascular disease. The Gentuity High-Frequency OCT Imaging System is the first commercially available OCT imaging system to deliver Total Vessel Imaging with the first 1.8F micro-imaging catheter. Gentuity and its' next-generation platform are paving the way for transformation in the intravascular imaging world. Designed to support the growing needs of the imaging industry, the platform incorporates AI and machine learning with the intention of creating "collaborative intelligence" to enhance ease of use and procedural success.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; iDose Travoprost, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication; and MicroShunt, an ab-externo device for treatment of open-angle glaucoma. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.

Glycostem Therapeutics is a Dutch biotech company established in 2007. Glycostem Therapeutics has developed the world's first GMP compliant NK cell platform that is ready for industrial scale-up.

Leveraging our deep experience in stroke medicine and bio-engineering, we have developed the world's most powerful and cost-effective solutions to save millions of lives impacted by ischemic stroke

Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, let's transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. A leader in essential plasma-derived medicines and other innovative biopharmaceutical solutions.

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America and the US. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of € 1.8 bn. More Information on www.grunenthal.com Jobs & Career: http://careers.grunenthal.com/ Imprint: https://www.grunenthal.com/en/footer-links/imprint Privacy: https://www.grunenthal.com/en/footer-links/privacy-statement-social-media This company profile is managed by Global Communications. In our commitment to transparency and the principles outlined in our digital ethics charter, Grünenthal wishes to inform you that generative artificial intelligence technologies are occasionally used to enhance content on this channel. Each content piece has been reviewed and edited by a team member before publication to ensure accuracy.

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 1000+ patients with brain tumors.

HanAll Biopharma is a global biopharmaceutical company committed to discovering and developing innovative treatments for various diseases. The company has entered into joint research and development agreements with other pharmaceutical companies to explore potential treatments. HanAll Biopharma is dedicated to advancing healthcare through strategic partnerships and cutting-edge research.

Biologics, Small Molecules

Jiangsu Hansoh Pharmaceutical Group Co., Ltd. was established in July, 1995. It has developed into a new pharmaceutical group featuring R&D, manufacture, sales and pharmaceutical investment of drugs. There are more than 40 products launched into the market which cover six therapeutic categories: oncology, antibiotics, psychotropic, antidiabetics, gastro-intestinal and cardiovascular area. Since its inception, Hansoh has evolved into a flagship enterprise for R&D and production in China, a Top 30 enterprise of China's Pharmaceutical Industry, and one of the most innovative pharmaceutical enterprises in China. Adhering to the concept of management innovation, technology innovation and product innovation, Hansoh will accelerate collection and fusion of development factors including top-level talents, innovative technology and lean manufacturing, along with peers in the international pharmaceutical field, hand in hand and shoulder by shoulder, to jointly endeavor bravely to contribute wisdom and strength to health of mankind.

Helaina isworking to grow mammary cells toproduce cultured human milkforhuman babies.

Helix BioMedix develops bioactive peptides based on specific natural cellular sequences for targeted topical efficacy. Our extensive library of proprietary peptide sequences can be used to treat a growing range of dermatological conditions including acne, rosacea, fungus and MRSA. Our mission is to enrich clinical practice and patient/consumer well being by developing topically-applied products which offer the health, beauty and safety benefits of our advanced bioactive small molecule peptide technology.

We are a start-up medical device company originating from ETH Zurich and are passionate about developing life saving therapies. Our mission is to develop a breakthrough medical device for the most urgent healthcare issues. Focusing on patients’ needs, we translate the most promising research to the clinics and ensure patient access to scientific progress as soon as possible. As pioneers we take courageous decisions and are shaping the future of medicine. We first focus on finding an efficient therapy for patients with sepsis, a devastating condition causing millions of deaths annually.

Hercules Pharmaceuticals, Inc is a fully independent pharmaceutical wholesale distributor accredited and licensed by the National Association of Boards of Pharmacy (NABP) in all 50 states. They serve the full spectrum of pharmaceutical care, including retail, compounding, and specialty pharmacy. Hercules Pharmaceuticals is committed to providing high-quality pharmaceuticals and exceptional customer service to their clients.

Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.

HistoSonics is a venture-backed medical device start-up company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company's new platform delivers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today's interventional and surgical modalities. HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders. In order to meet the highest international standards, Hua Medince developed a powerful internal research quality supervision system Q (QC/QA) based on the advanced open innovation model VIC (VC + IP + CRO).

Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Huma's technology has powered over 3,000 hospitals and clinics, with 500+ unique deployments across 70+ countries. The software has been used to engage and screen over 35 million individuals, with 1.8 million active users across its various products. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as working with most large pharma companies and CROs. The Huma Cloud Platform offers a technology infrastructure built on strong regulatory foundations to launch digital solutions for healthcare and research. Huma has achieved FDA 510(k) Class II, EU/MDR Class IIb, and Saudi FDA Class C regulatory clearance for its disease-agnostic flagship product, enabling rapid, code-free configuration with the ability to host AI/ML models.

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.

Impulse Dynamics is a fast-growing medical device company that has pioneered a new form of therapy for heart failure called Cardiac Contractility Modulation, or CCM. The Optimizer Smart is the first implantable device for the treatment of chronic heart failure in patients with normal QRS durations.

Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity. Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia. We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list. For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.

Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions. *Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

InGeneron is a clinical-stage biotechnology company developing novel, safe, and evidence-based cell therapies. We are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s own regenerative cells processed at the point of care for same-day treatment. We currently focus on helping patients impacted by orthopedic conditions and are conducting several clinical trials to validate our technology as a disease-modifying treatment. Based on more than 20 years of research, InGeneron is dedicated to developing therapies supported by clinical evidence and approved by the FDA.

Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems. Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer's, Parkinson's or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.

Innovative BioTherapies (IBT) is a small biotechnology company located in Ann Arbor, MI, focused on developing medical devices to solve unmet medical needs.

Inocras is a company for whole genome sequencing, providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretation. Focusing on cancer and rare diseases, we aspire to fundamentally change how the world treats genetically driven diseases with an unsurpassed WGS databank and an integrated platform for generating, collecting, and analyzing genomic data.

INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers`​ needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.

Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. Founded in 2000 (NASDAQ: PODD), Insulet operates with a customer-centric focus to supply high-quality products and expand the use of insulin pump therapy. Omnipod products are now available in 20+ countries around the globe. HIRING SCAM ALERT Recently, individuals impersonating Insulet Human Resources members have offered fraudulent interviews and job offers to unsuspecting candidates. To help protect you from these scam artists, please be aware that: • Insulet will never interview a candidate over RingCentral, similar messaging apps or social media (i.e. Google Hangouts, WhatsApp, Facebook Messenger, etc.), or via text message. • Insulet will never send a company check or ask an applicant to pay a fee or purchase at home work/training materials in connection with an application for employment. • Insulet will never provide excess money to an applicant and ask the applicant to write a check for repayment. If you have any doubt about a job offer or any other communication purporting to come from Insulet, please reach out to us directly at 978-600-7000. If you receive any type of communication on behalf of Insulet that seems inappropriate or suspicious, please report this activity to: www.iC3.gov or www.stopfraud.gov.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies affect the inner-workings of cells in the body. The Company leverages this intracellular approach to deliver innovative treatments for people living with complex psychiatric and neurologic diseases. WORK WITH US Patient needs are at the core of our efforts at Intra-Cellular Therapies and we are always looking for talented individuals who share our values to join our team. Please explore open positions by clicking the “Jobs” tab above.

Adjacent to a lumbar discectomy, the Barricaid® device is designed to close large defects in the annulus, which often lead to disc reherniation and/or disc collapse. Barricaid is a permanent implant with two components - a titanium bone anchor and a flexible polymer barrier. The barrier is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position. The Barricaid has been studied in a definitive – level 1B evidence - randomized superiority trial with over 550 patients enrolled (clinicaltrials.gov NCT01283438). The study focuses on patient at highest risk of reherniation and reoperation, enrolling only those patients with large defects (width >5 mm). The co-primary endpoints of reherniation and an 8-point composite of safety and effectiveness are evaluated at 2 years, with a parallel cost effectiveness analysis. Treated patients were found superior on both endpoints, with significantly lower rates of symptomatic recurrences (12% vs. 25%, p<0.001), index-level reoperations (9% vs. 16%, p=0.01), and device or procedure related serious adverse events (SAEs) (7% vs. 17%, p=0.001). Through two years, a total of 29 reoperations were performed in Barricaid subjects in comparison to 61 procedures in Controls. Study results are published in The Spine Journal, May 2018. Barricaid is FDA-Approved For full risk/benefit, see: www.barricaid.com/instructions-for-use

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries. The company was founded in Milan in 1938. The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400 and has a total turnover exceeding 300 million euros. Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

At JaxBio, we are revolutionising the way cancer is diagnosed and managed by making cancer detection simpler, quicker, and more precise, and we're doing that through our innovative blood test technology. Our unique blood test offers advantages over traditional methods and traditional liquid biopsies. Based on its high sensitivity together with low cost and simplicity, we can deliver results faster with improved accuracy. By improving screening and early detection capabilities for cancer, healthcare providers and patients can now make better informed decisions sooner when time is of the essence. We use novel artificial intelligence (AI) algorithms to identify sets of biomarkers that are effective in detecting various types and subtypes of cancer at different stages. Our tests aren't just for initial diagnosis; they're also valuable tools for monitoring disease status and predicting how well a patient will respond to therapy. Our platform technology can also be used in a range of diseases, including various types of cancer, neurodegenerative diseases, and heart diseases. Connect with us to learn more.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.

Jeil Pharmaceutical - Founded in 1959, Jeil has developed and supplied superior pharmaceutical products to promote the happiness and health of mankind and has contributed to the growth and development of the pharmaceutical industry in Korea. Jeil has been listed on KOSPI since 1988. As of 2018, Jeil is constituted of 1143 employees and has sales amount reaching above 680 billion Korean wons. The Central R&D Center established in 1980 forms the core of the R&D activities of Jeil. Currently, as of 2018, the new drug development laboratory, the pharmacology & toxicology laboratory, the organic synthesis laboratory, the formulation laboratory, and the analysis laboratory are actively engaged in conducting research into the complete manufacture and ingredients of innovative new drugs, incrementally modified drugs, and generic drugs. Jeil’s factory established in 1986 and located in Yongin-si, Korea was accredited as fulfilling KGMP in 1987, and produces tablets, capsules, injections, finished pharmaceutical products including patches, and Active Pharmaceutical Ingredients(APIs) such as anti-biotic ingredients, etc. The construction of new factory with the most up-to-dated facilities, which complies with EU-GMP and US-GMP, has been completed in 2016. In May of 2018, Jeil established Pharmaceutical Technology Research Institute, a formulation and analysis lab, at Yongin Technovalley in Yongin-si, Korea to further improve and invest in research and development of Incrementally Modified Drug (IMD) and generic products. Jeil, equipped with global-class research centers and production facilities, has been recognized for its outstanding value on the world market as well. In the ingredients sector, Jeil exports synthetic ingredients such as Cefditoren Pivoxil, Epinastine HCl, etc. to Japan and China, while also supplies finished products such as Kefentech Plaster (Ketoprofen), Cilapenem Injection (Imipenem / Cilastatin Sodium), etc. to more than 40 countries in ASEAN, Central and South America, Africa, etc. Within the South Korean market, Jeil operates a well-trained MR organization to cover the nation-wide market based on science and evidence, and thereby has become a supplier of over 70 prescription drugs and over 30 over-the-counter drugs. Beginning in the period between 1970 and 1980, Jeil has engaged in technological partnerships (licensing) with global pharmaceutical companies to provide the domestic market with outstanding new drugs. It has also been the first Korean company to engage in co-promotion successfully with the globally renowned company Pfizer, executing a win-win strategy with our overseas collaborative partners and thus winning recognition as an advanced pharmaceutical company adapted to internationalized business practices. We thank all of the visitors to our Jeil’s homepage for their interest and encourage you to contact us for further business progress.

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Kamada is a growing commercial-stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions. The company is a leader in the specialty plasma-derived field focused on diseases with limited treatment alternatives, with 6 FDA-approved products selling in over 30 countries. The company is advancing an innovative development pipeline targeting areas of significant unmet medical need.

At Kestra, we stand for patients at-risk and the people who care for them. Together we work to protect, support, and empower them with wearable technologies, tools, and better answers as they navigate life's most challenging medical events. Cardiovascular disease is the number one cause of death globally. We're taking a fresh approach to cardiac monitoring and delivery of definitive therapy with wearable products and applications. We aim to make the entire recovery process easier for patients by bringing comfort and assurance to them—along with advanced clinical insights and tools to their medical care teams. Kestra is a privately held, Bain Capital portfolio company, headquartered in Kirkland, Washington USA. Visit us at www.kestramedical.com

KiOmed Pharma is a biotechnology company based in Belgium that focuses on developing, manufacturing, and distributing chitosan-based medical devices. The company, a spinout from KitoZyme, utilizes exclusive natural chitosan chemistry to create solutions for high-impact medical conditions, particularly in osteoarthritis, dermatology, and ophthalmology. Headquartered in Herstal, Liège, KiOmed Pharma emphasizes therapeutic innovations through its proprietary KiOmedine® technology platform. One of its key products is KioMedine(vs)one, a single-injection soft implant designed to relieve pain and improve mobility in knee osteoarthritis patients. The company is also developing additional products targeting joint health, skin aging, and eye-related disorders. KiOmed Pharma maintains a commitment to biocompatibility and safety by using non-animal-derived chitosan in its formulations. In April 2024, KiOmed Pharma formed a strategic alliance with Aptissen to globally commercialize KioMedine(vs)one, enhancing patient access to its treatments while generating revenue through royalties and milestone payments. Under the leadership of CEO Houtaï Choumane, the company aims to create long-term value and improve patient outcomes in chronic diseases.

Kissei Pharmaceutical - Approaching R&D with Passion and Creativity “Pharmaceutical company cannot exist without R&D.” These words have been passed down at Kissei ever since the company was founded. They show that R&D is an essential and central part of our work, The phrase also expresses the passion of each and every Kissei Pharmaceutical - Kissei employee for the development of new innovative drugs, in the hope that those drugs will help as many people as possible recover as quickly as possible from disease and live lives full of laughter and joy. We aim to develop and supply innovative pharmaceutical products that contribute to the improvement of medicine and the health of people around the world by aggressive incorporation of leading-edge technology and collaborations with our foreign and domestic partners.

KoBioLabs is recognized for its international level of microbiome therapeutic technologies. In particular, our researchers have a distinctive position in the microbiology field globally with their presence in the ongoing International Human Microbiome Consortium [IHMC].

KOELIS has assisted urologists and radiologists from around the world in their routine clinical practice since 2006, providing the latest technology for personalized prostate cancer planning and management, from biopsy to active surveillance and treatment. Focused on developing advanced, targeted and less invasive solutions, KOELIS is committed to creating and bringing to the market a new paradigm in prostate cancer care, where physicians can offer the most personalized answers to their patients, avoiding any under or overtreatment and preserving quality of life. Thanks to cutting-edge imaging tools like Trinity® cartographer, which combines multiple imaging modalities with full 3D ultrasound, any suspicious lesion is characterized in a detailed 3D prostate map, offering a comprehensive and multiparametric approach and enhancing diagnostic confidence. The team at KOELIS innovates every day in collaboration with world-renowned universities and hospitals to offer physicians new advancements in imaging and a greater field of view, a must-have in active surveillance and targeted treatment. Based in Grenoble and Princeton, KOELIS technology has been featured in more than 50 clinical publications and treats more than 300,000 patients worldwide, including patients in Europe, United States, Canada, Japan, Australia, South America and the Middle East.

Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible. The North America organization includes three offices in New Jersey and California that focus on drug discovery, product development, and commercialization. Together, we work as a collaborative team to understand clinical needs and advance innovations that have a profound impact on patient lives. Our growth in North America relies on entrepreneurial team players who are willing to share their expertise and ideas in an environment that prioritizes innovation, diversity, integrity and “wa.” Each person plays a significant role in shaping the work we do and the results we deliver.

Lantheus Holdings, Inc. (NASDAQ: LNTH) is the parent company of Lantheus Medical Imaging, Inc. (LMI), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs.

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion. Disclaimer: This site is intended for discussions about LEO Pharma and the various initiatives LEO Pharma is involved in. Due to regulations, discussions about pharmaceutical products are not allowed on this site. All content must be factual and non-promotional. LEO Pharma reserves the right to moderate or remove any content that may be inconsistent with legislation, industry ethics and regulations and LEO Pharma’s values, including: - profane or vulgar language - insulting or offensive comments, such as displays of racism, calls to violence, hate propaganda, etc. - commercial or political advertising - copyright infringements, or any violation of the rights of external parties - automatically-generated content i.e. spam - wrong/false statements For more information about our social media principles, please visit https://www.leo-pharma.com/social-media-principles

LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care. With most of its products indicated for serious and rare diseases, LFB is a major player in this area. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 5th worldwide and is also among the leading European companies for the development of new-generation proteins and treatments based on biotechnologies. With a sustained investment in research and development, the LFB Group bases its strategy on its international deployment and the design of innovative therapies.

LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials such as cathodes, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem is committed to reaching carbon-neutral growth by 2030 and net-zero emissions by 2050 by managing the impacts of climate change and making positive contributions to society through renewable energy and responsible supply chains.

Liberate Medical is a medical device company that develops neuromuscular electrical stimulation technology to improve the quality and reduce the cost of care for patients with pulmonary disorders. Liberate's lead product, the VentFree™ respiratory muscle stimulator. Invasive mechanical ventilation commonly weakens the breathing muscles, increasing the need for further ventilator support. VentFree applies proprietary, non-invasive, electrical stimulation to the expiratory muscles in synchrony with exhalation while a patient is on mechanical ventilation. This breakthrough therapy, which is quick and simple to use, is intended to reduce abdominal muscle atrophy and the time taken to liberate patients from mechanical ventilation. Reduced days on mechanical ventilation can potentially lead to reduced morbidity and mortality, improved quality of life, and considerable savings for the health care provider.

Loci Orthopaedics develops innovative orthopaedics medical technologies to meet large unmet clinical needs.

Lumenis creates and commercializes innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. We have successfully introduced solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods. We are BeautyTech pioneers, empowering people by broadening the horizons of health and celebrating beauty that matters. Lumenis has a rich history of defying technological boundaries, redefining standards within our domains, and transforming people's lives - both inside and out. Our drive for innovation stems from an uncompromising commitment to providing best-in-class technologies and solutions designed to achieve excellent results. Lumenis has a solid global footprint in developed and emerging markets and sales in over 100 countries. Headquartered in Israel and with offices on four continents, our team consists of nearly 1,500 professionals worldwide.

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies, neurodegenerative diseases, and inflammation. The firm’s strength is rooted in extensive and successful experiences in both the pharmaceutical and biotech industry, along with a solid academic track record.

Magenta is developing miniaturized catheter-mounted axial flow-pumps for mechanical circulatory support indications, based on Magenta's core technology of self-expanding impellers and pump heads. Our percutaneous Left Ventricular Assist Device (pLVAD) is a next-generation low-profile arterial pump, intended for temporary support of patients undergoing high-risk coronary interventions and the treatment of patients admitted with cardiogenic shock.

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com. Mission: Managing Complexity. Improving Lives. Values: Quality, Integrity, Service Principal Executive Office: Mallinckrodt plc Damastown Industrial Estate Mulhuddart, Dublin 15 Ireland U.S. Headquarters: 675 McDonnell Blvd. St. Louis, MO 63042 USA Website: www.mallinckrodt.com Stock Ticker: MNK Corporate Blog: http://blog.mallinckrodt.com/ Careers Website: www.mallinckrodt.com/careers Investor Relations: http://www.mallinckrodt.com/investors

Materna Medical is a novel OBGYN platform company defining a $6B market with core technologies addressing unmet needs in women's pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical's mission is to empower women to protect their pelvic health.

May Health is a healthcare company that is developing a modern approach to PCOS.

Melodi Health offers novel technologies that improve patient outcomes for women undergoing breast surgery. Melodi Health manufactures the Melodi Matrix, designed to support the soft tissue space around a prosthetic device while delivering antibiotics to the surrounding tissue. The Melodi Matrix is currently an investigational device being studied in a prospective, multi-center, randomized, controlled clinical trial in breast reconstruction.

Developer of bio-engineered surgical implants designed to facilitate new tissue growth and also aid in connective tissue repair. The company's implants specialize in viable alternatives to conventional ACL reconstruction for patients who have sustained any kind of leg injury, enabling surgeons to perform surgery to restore normal anatomy and function of the knee.

For over 30 years, Miltenyi Biotec has been a major provider of products and services that drive biomedical research and boost cell and gene therapy. More than 4,700 employees in 23 countries combine excellence in research with innovative products to create cutting-edge solutions that make cancer and other disease history. Our expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. At Miltenyi Biotec, scientists, engineers, software developers and many other professionals work together to improve human health by providing smarter cellular technology solutions to researchers and clinicians worldwide.

Miracor Medical SA is a European medical device company dedicated to improve clinical outcome of patients with impaired cardiac function. Miracor develops and studies the PiCSO® (Pressure-controlled intermittent Coronary Sinus Occlusion) Impulse System, which is used as an adjunctive technique during the primary PCI procedure for acute myocardial infarction patients. PiCSO therapy seeks to improve coronary microvascular function to reduce infarct size and salvage myocardium, thereby improving outcomes of ST-elevation myocardial infarction (STEMI) patients. Recent Clinical Studies have successfully demonstrated the safety and positive effects of PiCSO on coronary microvascular function and infarct size reduction in STEMi patients. The company is conducting further clinical trials in Europe and plans to initiate a US IDE randomized controlled trial in 2023. Miracor has won several innovation awards and completed financing rounds raising venture capital and public funding. The company was founded in May 2008 by Professor Dr. Dr. Werner Mohl and the European venture capital firms Earlybird and Delta Partners.

At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.

Monteris is a private equity backed neurosurgical company focused solely on diseases of the brain. The company was founded in Winnipeg, Canada in 1999 to create neurosurgical technology that, when used by neurosurgeons, would allow them to ablate brain tumors and lesions that may be difficult to approach via traditional methods. The NeuroBlate® System is a minimally invasive robotically controlled laser thermal therapy that uses MRI-guided laser light to ablate (destroy) unwanted tissue in the brain where a lesion, or abnormal tissue, originates. Monteris has offices in Minnetonka, Minnesota, USA and Winnipeg, Manitoba, Canada.

For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, emerging animal diseases, and, most recently, Covid-19 — as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-ireland.com

We aspire to be the leading healthcare company focused on redefining care for women’s health and prostate cancer. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We strive to improve the lives of millions of people, while building an innovative, dynamic, and collaborative company where employees thrive.

Nanoscope is focused on proprietary ambient light activated optogenetic therapy to restore vision in people suffering from all forms of Retinitis Pigmentosa.

NeoCura is a high-tech enterprise that relies on AI technology to create an RNA technology platform and conduct R&D of innovative drugs. The company has built multi-omics big data acquisition platforms and multiple bioomics databases. It uses AI and bioinformatics technology to conduct in-depth drug target mining and fully automated drug design for innovative RNA technology platform upgrades and drug research. It has established leading R&D centers and production centers in Beijing, Shenzhen, and Guangzhou to support pipelines development, platform upgrades, and clinical demand.

RM-581, a small molecule in early developpement of a new class (the aminosteroids), demonstrated its ability to block the progression or even reduce the size of cancerous tumours that are difficult to treat with conventional chemothérapy. Le RM-581, une petite molécule en développement préclinique d'une nouvelle classe (les aminostéroïdes), a démontré une capacité à bloquer la progression ou même réduire réduire la taille des tumeurs cancéreuses difficiles à traiter avec la chimiothérapie classique.

At Neuralace Medical, we are driven to accelerate the world's transition to sustainable, non-invasive chronic pain relief. What do we believe that very few others do? We fundamentally believe that overcoming chronic pain is inevitable. With our bold vision, we are challenging the conventional thinking the healthcare industry is currently laden with to implement innovations and technological advances to improve the overall quality of life of individuals by maximizing pain relief and minimizing side-effects, redefining the very concept of pain therapy which can leave patients with more side-effects than benefits. NeuraLace is not just a device developer, but also a technology company with a focus on medical innovations that can significantly restore the quality of life patients suffering from chronic pain. Our inherent interest in innovation and deep technical knowledge, along with the partnerships we are currently developing, will allow us to realize our vision and create something truly special. We are a startup medical technology company here to make a dent in the world of pain therapeutics!

Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.

Neurescue is a medical device startup pioneering an improved treatment of cardiovascular emergencies. The company has been awarded several innovation awards and large grants.

Neuroelectrics® is a digital brain health company that innovates at the intersection of neuroscience, physics, machine learning, and hardware. We have developed wireless EEG and tDCS/tACS/tRNS stimulation devices with up to 32 channels, amongst other products encompassing software and research services, with the purpose of monitoring and enhancing brain health.

Neurogene is focused on developing life-changing genetic medicines for patients & families affected by rare, devastating neurological diseases.

NeuroNOS is a pioneering biopharmaceutical company developing a novel drug for Autism Spectrum Disorder (ASD) and other neurological conditions. The company’s small-molecule therapy is based on a technology from the Hebrew University. It is designed for subcutaneous injection or oral administration and aims to regulate nitric oxide (NO) levels in the brain, a mechanism that has shown significant promise in preclinical studies. NeuroNOS has demonstrated that balancing NO levels can lead to both behavioral and biological improvements in animal models of autism. The company is actively advancing its preclinical research, with plans to enter a Phase 1 human clinical trial in 2026.

Neurotrigger develops the next generation wearable powered muscle re-education stimulation system. Re-educating muscles is important for facilitating and improving muscle performance and muscle's range of motion, and for the prevention or retardation of disuse atrophy.

Based in Belfast, Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world's greatest health challenges! Modius is the first product from Neurovalens which successfully launched in August 2017 on Indiegogo. Modius was designed to help improve the lives of people who struggle with their weight by using neuro-technology to help make weight loss easier.

Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera's minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.

Building Brain Computers Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca'​ Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. ​ Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics and biotechnologies.

Their vision is to develop clinically validated ‘therapeutic wearables’ that allow for medical devices to become a true alternative to pharmaceuticals in the management of chronic neurological disorders.

Nonagen Bioscience is a biotechnology company that specializes in developing first-in-class diagnostics for early detection and prediction of human cancers.

Nordic Pharma is a privately owned, medium-size, fully integrated Pharma company with a history of internal product development and acquisitions. We focus on the development and commercialization of specialty products, which include, but are not limited to, niche hospital and orphan products, to address unmet medical needs. Our expertise relies on the development and sales of our own products, but also on partner products acquired at various stages of development. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: Rheumatology, Women's Health and Critical Care (Anaesthesia, Haematology, Oncology). We have established deep roots throughout Europe, and more recently, expanded outside of Europe, with the creation of an affiliate in Canada. Our driving force is about innovative and efficient products to fight diseases. We strive to bring solutions to specific unmet medical needs, contributing to improved patient care. Nordic Pharma's values of Commitment, Ambition, Respect, Reliability, Integrity and Agility describe our culture and standards and guide us in our way of working.

Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. Currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. The Company’s approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. The Company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies. The Company’s platform technology, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system. The dendritic cells are extracted from the body, loaded with tumor biomarkers or ‘‘antigens’’, thereby creating a personalized therapeutic vaccine. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. The Company’s lead product candidate is DCVax®-Brain which targets Glioblastoma Multiforme (‘‘GBM’’), the most lethal form of brain cancer. DCVax®-Brain has entered a Phase II FDA-allowed clinical trial, which is designed and powered as a pivotal trial (i.e. a trial from which a company may go directly to product approval). Following this trial, the Company anticipates filing a biologic license application (or ‘‘BLA’’) with the FDA for DCVax®-Brain. DCVax®-Prostate, which targets hormone independent (i.e. late stage) prostate cancer, has also been cleared by the FDA to commence a Phase III clinical trial, which is also designed and powered as a pivotal trial.

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community. Notable's proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product's medical impact and commercial value faster, higher, and more likely than traditional drug development.

Novartis is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 106,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.

We’re focused on using our proven vaccine technology to protect health by developing our R&D assets and establishing partnerships. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our mission of ensuring broad access to our vaccines. It’s more than our job. It’s our passion. Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

We are Nuwellis, (Nasdaq: NUWE) formerly CHF Solutions. Our solutions go beyond chronic heart failure, so we've rebranded to reflect our therapeutic focus areas: heart failure, critical care, and pediatric fluid imbalance. We are a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. Our Aquadex SmartFlow® System gently removes fluid from adult and pediatric patients weighing 20 kg or more. Nuwellis consists of a purpose-driven team that puts patients and their providers at the center of everything we do. This is the new well. And for those whose lives and life's work are transformed by our fluid management technologies, the new well is everything. Nuwellis is headquartered in Eden Prairie, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions (Nasdaq: CHFS).

Nyxoah is a pioneering medical device company developing a breakthrough therapeutic solution for the treatment of Obstructive Sleep Apnea (OSA). Our mission is to become a world leading company by offering unique patient-centric neuromodulation solutions, developed by passionate and exceptionally driven people Nyxoah's therapy Genio® offers: - Unparalleled clinical efficacy - Increased patient comfort, therapy compliance and quality of life - Minimally invasive approach, thus streamlining patient flow and reducing surgery related risks - Positive health economics outcomes by reducing the burden of OSA and its comorbidities

OCON Therapeutics develops innovative and safe intra-uterine medical solutions that are inspired by women’s bodies and anatomy, to better the lives of women everywhere. In the past decade we have developed the IUB™ platform, our proprietary intrauterine ball-shaped technology, utilising super-elastic alloy Nitinol to carry long lasting hormone-free contraception and other drugs. OCON’s first product, the IUB™ Ballerine®, is a CE approved copper-based hormone-free intrauterine contraceptive, effective for up to 5 years, and already in use by over 100,000 women in 24 countries, including EU member countries, South Africa and Israel. The Company is currently enlisting patients for its phase II clinical trials with the IUB™ SEAD, a disposable, point of care therapy for the treatment of abnormal uterine bleeding (AUB), affecting 25% of women in the reproductive age. The SEAD (Spherical Endometrial Ablation Device) is designed to be a pain-free, non-invasive and cost-effective alternative for aggressive, invasive, painful and costly ablation procedures hundreds of thousands of women currently endure. In addition, we are working on a strong pipeline of more IUB™ based drug products, using the frame for myomas and other uterine indications. OCON’s technology platform and products are protected by a broad portfolio of patents and trademarks.

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 195 plasma donation centres across Europe and the US. Octapharma has 40 years of experience in patient care. Check our community guidelines: https://bit.ly/3M8ioml

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™. Ocular Therapeutix has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Ocular Therapeutix has a commercially available drug product, DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use. DEXTENZA is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis; the product is currently being marketed through a fully integrated specialty sales force. Ocular Therapeutix’s lead clinical program AXPAXLI™ (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI, is currently being developed to treat wet AMD and diabetic retinopathy; other indications may also be pursued in due course. Other clinical programs include PAXTRAVA™ (travoprost intracameral implant), also referenced as laboratory code OTX-TIC, for intracameral injection, for the treatment of elevated intraocular pressure in primary open-angle glaucoma or ocular hypertension, OTX-CSI (cyclosporine ophthalmic insert) for intracanalicular use, for the chronic treatment of dry eye disease, and OTX-DED (dexamethasone ophthalmic insert) for intracanalicular use, for the short-term treatment of the signs and symptoms of dry eye disease.

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA has grown into a corporate group of companies with world-renowned expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data interpretation software, and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – Biosequence and IntegraGen – are based in Spain, France and the United States. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.

Ophiomics is a Biotech company developing new diagnostic products and services integrating bioinformatics and genomics in support of diagnostic, prognostic, pharmacogenomics and clinical follow up in liver cancer.

OPTITHERA was founded in 2016 and has analyzed data from more than 20,000 type 2 diabetes patients from 20 countries. Based on these clinical studies and with the help of artificial intelligence, researchers were able to develop a genome test that can inform your physician if you are at risk of developing complications related to type 2 diabetes.

Orchestra BioMed biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine.

"Living Organs For Life"​ Transforming transplantation with the OrganOx metra®. A transportable, automated ex vivo liver perfusion device. The core technology employed by the OrganOx metra® has been in development for over 15 years. During this time both of the founders (Professor Peter Friend and Professor Constantin Coussios) have driven the development of organ preservation and maintenance, formerly at the University of Cambridge and latterly at the University of Oxford. OrganOx Limited was founded in April 2008 as a spin-out from the University of Oxford. Conventional cold preservation involves storage of the liver at 4˚C, using a non-physiological perfusion solution that aims to minimise liver decay. By contrast, warm preservation seeks to re-create an environment that mimics the human body by continuously perfusing at physiological pressures and flows with oxygen-carrying red cells at 37˚C and providing nutrition. The liver is therefore functional during the preservation period, producing bile, metabolizing glucose and maintaining a physiological pH. This enables objective assessment of organ performance prior to transplant, extended preservation times, and the potential use of organs that are presently being discarded.

Ortho Dermatologics is one of the largest prescription dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and corticosteroid-responsive dermatoses products. See our community guidelines at https://www.bauschhealth.com/social-media/.

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. Website: www.ossdsign.com Newsroom: https://news.cision.com/ossdsign-ab (Always consult Instructions for Use which accompany the products for complete indications, contraindications, warnings and precautions.)

PathMaker Neurosystems is a near-commercial stage neuromodulation company founded to commercialize recent advances in the development of non-invasive devices for the treatment of patients with serious neurological conditions. The company's technology is based on the premise that electrical fields can be used to stimulate the nervous system in a non-invasive manner, offering the potential to treat a wide range of neurological disorders.

We are on a mission to build a comprehensive product portfolio dedicated to women's intimate health. Our approach is rooted in the ability to diagnose, treat, and prevent concerns, blending science with aesthetically appealing and beautiful products. We firmly believe women's intimate care should be grounded in scientific exploration. This commitment to research ensures that our products are effective and backed by a robust foundation of research and knowledge. Join us on a movement to redefine women's intimate health.

Developing innovative catheter technology to treat acute ischemic stroke, providing superior clinical outcomes in shorter procedural times.

Persephone is pioneering the use of synthetic biology for microbial products that impact patient and infant health. We are building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler PhD, and Steve Van Dien PhD.

Perspectum's imaging solutions are safe, fast, and can offer more comprehensive diagnostics. We help doctors understand complex data and help deliver precision care to more patients. We believe the voice of the patient matters and that each case is unique. Our goal is to enable health care providers to tailor precision medicine to the needs of the individual.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Welcome to the Phagenesis LinkedIn page!  At Phagenesis, we are dedicated to transforming the way dysphagia is treated. Dysphagia, or difficulty swallowing, can be a debilitating condition that affects millions of people worldwide. We believe that everyone deserves the ability to enjoy their meals and live their lives to the fullest, which is why we have developed the Phagenyx - a revolutionary product that uses Pharyngeal Electrical Stimulation (PES) to treat dysphagia.  The Phagenyx is a simple, non-invasive device that stimulates the nerves in the pharynx, helping patients regain control of their swallowing function. Our product has been rigorously tested in clinical trials and has been shown to significantly improve swallowing ability in patients with dysphagia.  As a company, we are committed to advancing the field of dysphagia care through innovative technology and evidence-based practices. We work closely with healthcare providers and patients to ensure that our product meets the highest standards of safety and efficacy.  We are proud to be changing the paradigm of dysphagia care, and we invite you to join us in our mission to improve the lives of millions of people around the world. Follow our page to stay up-to-date on the latest news and developments in dysphagia care, and to learn more about the Phagenyx and how it is helping patients overcome dysphagia.

PharmaEssentia Corporation, based in Taipei, Taiwan, is a rapidly growing, fully integrated global biopharmaceutical innovator. Leveraging proven scientific principles and deep expertise in commercializing medicines, the company aims to deliver biologics for challenging diseases in hematology, oncology and immunology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea.

Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India. Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.

Phoenix Nest Biotech is a biotechnology company that focuses on treating Sanfilippo Syndrome by collaborating with leading academics and utilizing licensed key technologies.

Polares medical is a medical device company with a novel device for treating mitral valve regurgitation.

We are a clinical-stage, privately held medical technology company developing a transformational neuromodulation platform to treat diseases of undesired neural activity.

Probiotical is an Italian family-owned company specialized since 1985 in probiotics manufacture, from the raw material to the finished products, with very high quality, guaranteed stability and scientifically backed strains. We are driving innovation in a variety of functionalities and technologies. We offer our customers wide opportunities of customization and range extensions for probiotic blends and finished products ready-to-market, either under Probiotical's brand or in private label.

Progenitec is a healthcare company that facilitates faster healing of chronic wounds through accurate and fast diagnosis.

Proteomedix enables personalized medicine by developing non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies. The first product is a blood-based test for the early diagnosis of prostate cancer. The main benefit of this test is a significantly higher accuracy compared to today's clinical standard (blood-based PSA test). This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.

Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1 Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.1 1. Criner G et al AM J Resp Crit Care Med 2018, Published on 22-May-2018 as 10.1164/rccm.201803-0590OC Brief Statement: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.

Pulse Biosciences is the inventor and sole proprietor of Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. We are committed to health innovation that has the potential to improve and extend the lives of patients. Our proprietary Nanosecond Pulsed Field Ablation technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The people at Pulse Biosciences are some of the top experts in pulsed electric field technologies and have a broad range of engineering expertise across multiple medical device domains and will utilize nsPFA™ technology to treat a variety of applications for which an optimal solution remains unfulfilled. We have a deep and broad IP portfolio with over 130 issued patents globally owned and licensed. With this growing patent portfolio surrounding our innovative technology, Pulse Biosciences seeks to aggressively realize the potential of Nanosecond Pulsed Field Ablation technology by building a rich pipeline of transformative commercial applications.

PulseMedica has developed a proprietary real-time 3D imaging and laser targeting system for precise retinal surgery. Our patented next generation ultrafast femtosecond laser ophthalmic treatment will enable treatment for retinal diseases such as age-related macular degeneration (AMD) and glaucoma, for which there is currently no cure. PulseMedica is a company based out of Edmonton, AB, Canada.

Purdue Pharma’s bankruptcy case was heard before the Supreme Court of the United States in December 2023. In June 2024, the Court voted 5-4 against third-party releases contained in the Plan of Reorganization. The decision does nothing to deter us from the twin goals of using settlement dollars for opioid abatement and turning the company into an engine for good. We are reaching back out to creditors and renewing our pursuit of a resolution that delivers billions of dollars of value for opioid abatement and allows the Company to emerge from bankruptcy as a company with a public-minded mission. The Supreme Court’s decision does not affect Purdue’s operational stability or our ability to produce medications safely and effectively. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners and customers. The company will continue serving patients who rely on our medicines, and working to introduce new medicines that will help save and improve lives.

Qilu Pharmaceuticals is a leading Chinese pharmaceutical company founded in 1958, recognized as one of the top three players in China's pharmaceutical industry. The company operates as a vertically integrated enterprise, focusing on human medicines, veterinary medicines, and crop protection products. It has 12 subsidiaries and 11 manufacturing sites across China. Qilu's product portfolio includes over 300 finished dosage forms, making it a prominent manufacturer of injectables and solid-dose medications. The company also produces a wide range of active pharmaceutical ingredients (APIs) and has a robust pipeline with more than 200 generic drugs, 20–30 biosimilars, and 80–90 innovative drugs in development. With a global reach, Qilu exports products to over 100 countries and has established subsidiaries in the U.S., Europe, and Brazil. The company employs over 39,000 people worldwide, with a strong emphasis on affordable medicines and improving global health.

Radialis is advancing precision medicine by providing the next generation of organ-targeted positron emission tomography (PET).

We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius' lead product, TYMLOS® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; and the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer out-licensed to Menarini Group.

When treating stroke, procedural time and patient safety are critical. Utilizing advanced technology backed by clinical data, Rapid Medical expands what's possible in neurovascular treatment by offering interventional devices that are fully visible and adjustable in the brain. The result? The unique ability to tailor the procedure to every patient.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Aspiration System*, which includes a novel aspiration pump and catheters to allow rapid and consistent removal of blood clots from the brain. The RapidPulse logo and the word mark RapidPulseTM are trademarks of RapidPulse, Inc., and are the subject of applications pending in the United States and internationally. *The RapidPulseTM Aspiration System is not cleared for sale in the United States.

The CLIA-certified Razor Genomics Molecular Prognostic Assay is helping with precision management of the world’s deadliest cancer

RECKITT BENCKISER GROUP PLC is a Consumer Goods company that offers a wide range of household, healthcare, and hygiene products.

Recordati has been at the forefront of life-enhancing and life-changing medicines for almost 100 years. With its beginnings in a family run pharmacy in Correggio, Italy in the 1920s, Recordati is now a global pharmaceutical force, listed on the Italian stock exchange, with over 4,300 employees. We are a group of like-minded, passionate individuals who go to extraordinary lengths for our partners, customers, investors and the people across the globe who we serve. We develop and commercialise medicines to serve people living with common diseases, as well as those living with some of the rarest, in around 150 countries. At Recordati, our mantra is simple. We’ve always believed that health, and the opportunity to live life to the fullest, is a right, not a privilege. Whether that is for common diseases or the rarest – we want to give people the opportunity to be the best version of themselves. This drive will never stop. Together, we will always be reimagining tomorrow – with new ideas, new technologies and new innovations to fight diseases. Recordati. Unlocking the full potential of life.

The company uses biology-guided radiotherapy to detect and respond to signals emitted from cancer cells, and use them to guide treatment.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.

restor3d enables surgeons to improve the reconstruction and repair of the human body through 3D printed implants with enhanced anatomical fit and superior integrative properties. Leveraging expertise and experience in 3D printing of key biomedical materials spanning a wide range of properties, restor3d seeks to improve medical device solutions.

Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings. We recently expanded our aesthetics portfolio to include digital services with the acquisition of an innovative fintech platform. We have assembled a team of motivated, talented professionals who collectively aim to transform patient experiences and disrupt the status quo. Exceptional talents with passion, creativity, and dedication to improving lives will immediately contribute to our ambitious pipeline and unique culture. Our employees work on challenging projects in a supportive environment that provides opportunities for growth and development.

RevBio was started with one goal in mind—to end medicine's 50 year search for a biocompatible bone adhesive. Effective for bone-to-bone as well as bone-to-metal wet field applications, Tetranite® is a revolutionary biomaterial that promises to transform bone repair—for both patients and clinicians. Inspired by the marine animal the sandcastle worm, Tetranite is simple chemistry. Bioengineered from the worm's secreted protein, our synthetic adhesive is the only patented biomaterial which satisfies both the required and desired properties for a bone adhesive: wet field performance, multi-surface bonding, rapid mechanical stability, and controlled biodegradability. The properties of Tetranite™ include the ability to provide immediate fixation of bone to bone and bone to metal. This adhesive has been shown in multiple animal studies to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices. Existing data has also shown that Tetranite™ is reabsorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth over time.

ReVivo Medical, LLC is an early-stage medical device development company. Our initial focus is on an array of implantable devices capable of improving treatments for back and neck pain. Our unique designs rely on the biomechanics of load sharing to promote bone fusion. They have been designed with the challenges of the surgical procedure in mind. Market Background. Lower back and neck pain are the leading causes of disability world-wide. In the United States alone, there are more than 465,000 spinal fusion surgeries (of all types) performed each year. Most conventional surgeries use interbody cages that fill the space between the vertebrae and plates (akin to splints) that are implanted to hold the vertebrae in place while the spine heals. Worldwide, the spinal fusion device market is $6.4 billion. With the current economics of medicine in the United States, additional challenges have been placed on spine surgeons. Reimbursement rates are reduced and are often tied to outcomes. Surgeons need to constantly improve their results and be more efficient in the operating room, thus they are seeking new products which add value while reducing cost. Customer Value Proposition. Our initial two flagship products, an interbody cervical cage and an anterior cervical plate are innovative, next generation designs. It is anticipated that they will:  Accelerate patient recovery time.  Reduce the complexity and time required for surgery.  Achieve manufacturing costs comparable to premium implants.  Have greater appeal than the commonly used PEEK material (for our cages).

RiboNova is a privately-held biopharmaceutical company based in the Lankenau Institute for Medical Research near Philadelphia, Pennsylvania. Their product pipeline includes a Phase-2 ready small molecule drug for the treatment of all forms of genetically-confirmed mitochondrial disease and a proprietary drug discovery platform that targets transfer RNA with novel precision medicines for the treatment of mitochondrial and other diseases.

Ridgeback Biotherapeutics is a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases. The team at Ridgeback is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions. Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company; all funding for Ridgeback Biotherapeutics has originated from Wayne and Wendy Holman; two science driven individuals who invest in technologies that they believe will make the world a better place.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

Rubix LS: The Health Outcomes Architect At Rubix LS, we drive innovation in clinical research, drug development, and public health by combining cutting-edge science, real-world data, and inclusive patient engagement. Our work is structured around three core pillars: 🔹 Investigator-Led Research – We conduct our own research and develop targeted solutions to accelerate new therapies and improve health outcomes. 🔹 Clinical Research Services – We collaborate with biotech, pharma, and life sciences companies to manage clinical trials, support regulatory submissions, and enhance patient diversity in research. Our work is powered by 18M patient data sets and 369M patient data points. 🔹 Government & Public Health – We partner with federal agencies and public health organizations to develop policies, improve disease surveillance, and advance health equity through data-driven solutions. Leveraging Environmental & Geographic Insights To better understand health risks and intervention strategies, we integrate: ✅ DoE data to analyze long-term environmental exposures. ✅ USDA data to study the impact of food and nutrition on health. ✅ Heat Sink data to model cancer risk and environmental disease patterns. At Rubix LS, we don't just conduct research—we build pathways to better health by ensuring therapies are developed, tested, and delivered with precision, equity, and impact. 🔗 Learn more at our website.

RxFunction®, Inc. is a medical device company with a mission to design and market medical technologies that improve balance, increase mobility, and enhance confidence for patients. Walkasins® Lower Limb Sensory Prosthesis is clinically proven to improve gait and balance, and reduce the risk of falls. Walkasins replaces part of the lost nerve function for the feet. It is intended for individuals who experience numbness in their feet and struggle with mobility problems due to peripheral neuropathy. Walkasins is only available by prescription. To learn more, please visit us at www.rxfunction.com. RxFunction created Walkasins by building upon patented technology developed by co-founder and scientist Lars Oddsson, PhD. Development of Walkasins was supported by Small Business Innovation Research grants from the National Institutes of Health and is manufactured in Minnesota. RxFunction is the exclusive provider and manufacturer of Walkasins. Caution: Individual results and activity levels while using Walkasins may vary depending on many factors. There are risks associated with the use of this product and there are certain individuals who should not use the product. Only a qualified clinician can tell you if this product is appropriate for you and your individual circumstances. Please consult with your healthcare team for complete information regarding benefits, risks, and possible outcomes.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company’s product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson’s diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), and in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals, Inc. and for China to Sperogenix Therapeutics. For more information, please visit the Company's website at www.santhera.com

Extended release formulation technology

Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don’t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.

SeaStar Medical is a commercial-stage medical technology company based in Denver, Colorado, focused on developing extracorporeal therapies to combat excessive inflammation in critically ill patients. Incorporated in 2020, the company aims to improve patient outcomes by transforming immune responses or removing harmful cytokines that contribute to organ failure. The flagship product, the Selective Cytopheretic Device (SCD), is designed to neutralize overactive immune cells and halt cytokine storms, which can lead to severe hyperinflammation. SeaStar Medical also offers QUELIMMUNE (SCD-PED), the first FDA-approved treatment for life-threatening acute kidney injury in critically ill pediatric patients. The company has received Breakthrough Device Designation for multiple therapeutic indications, facilitating a faster approval process. Led by a team of experienced professionals, including critical care physicians, SeaStar Medical targets critical care clinicians and hospitals, providing innovative solutions for managing severe inflammatory conditions.

SecondWave Systems is a pioneer in the emerging field of bio-ultrasonic medicine. The company is developing a first-of-its-kind noninvasive, wearable ultrasound stimulation platform that will give patients and their physicians a new option for treating debilitating or life-threatening disease.

Shape Memory Medical is dedicated to developing innovative embolization solutions for peripheral vascular, cardiovascular, and neurovascular markets. We are the first medical device company to introduce an FDA-cleared medical device utilizing shape memory polymer (SMP) technology (smart polymer) to a vascular market. We look towards what lies ahead, as we develop an aortic portfolio to address clinical needs and shape the future of sealing and healing.

The purpose of the Shionogi Group's corporate activities is, as expressed in the opening of its Company Policy, to "supply the best possible medicine to protect the health and wellbeing of the patients we serve."​ This eternal and unwavering corporate philosophy is a statement of our vision and value to society. To achieve and live by the Company Policy, we have formulated Action Guidelines, which all Shionogi employees share and embrace as norms for daily activities. Through activities based on the Company Policy and the Action Guidelines, Shionogi will continue to contribute to patients, physicians and other healthcare providers, shareholders and investors, and furthermore to society as a whole.

ShiraTronics is a forward-thinking medtech startup committed to revolutionizing the field of migraine medicine with our minimally invasive neuromodulation system. Our mission? To transform the lives of those facing Chronic Migraine by reducing headache days and restoring quality of life.

The simplicity of our design--born out of our extensive experience--comes down to the basic notion that traditional fixation techniques aren't strong enough and don't last. Our InSet™ approach to Glenoid fixation is revolutionizing shoulder arthroplasty and, more importantly, improving procedure longevity--ultimately changing patient's lives.

Solarea Bio is a clinical-stage biotechnology company in Cambridge, MA developing plant-based microbial solutions to some of the world's largest health problems. Solarea was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health. The Solarea breakthrough came from the combined efforts of the company's co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods, and their applications in inflammatory processes including the gut-musculoskeletal axis. Using powerful genomic and bioinformatic tools, Solarea is mining its novel microbial strain collection to identify synergistic combinations of microbes and prebiotic plant fibers to develop solutions for patients suffering from inflammatory processes.

Sommetrics, a privately funded company based in San Diego, develops products and services to treat airway problems that arise during medical procedures and during sleep. The company’s products are based on its patented aer+ technology, which uses negative pressure to hold a patient’s airway open through a comfortable, well-tolerated and non-invasive mechanism. For more information, visit www.sommetrics.com and follow the company on Twitter, Facebook and LinkedIn.

Our mission is to provide the next generation of sound medicine through proven ablative technologies that precisely deliver care while sparing healthy tissue. This next generation of care involves expanding our current HIFU technologies to treat a range of urological indications that balance treatment effectiveness and quality of life.

Sonendo, Inc. is a medical technology company based in Laguna Hills, California, dedicated to enhancing endodontic care. The company focuses on innovative solutions to treat tooth decay, utilizing minimally invasive techniques that help preserve natural tooth structure and improve patient outcomes. The core product, the GentleWave® System, employs broad-spectrum acoustic energy and fluid dynamics to effectively clean and disinfect root canal systems. This system includes the CleanFlow® instrument, designed to minimize tooth damage during procedures. Additionally, Sonendo offers TDO® Software for practice management, along with disposable consumables and maintenance services for the GentleWave systems. The company generates revenue through system sales, leasing, consumables, and service contracts, primarily targeting dental practices that specialize in endodontics and restorative care. Sonendo aims to transform traditional endodontic practices with its Sound Science™ approach, focusing on precision and reducing complications in root canal treatments.

ABOUT SONEX HEALTH "Refined simplicity" is the guiding principle behind Sonex Health, Inc., to drive efforts and innovations that result in elegant, effective solutions to some of the healthcare system's most pressing needs. Mayo Clinic physicians Darryl Barnes, MD and Jay Smith, MD and business operations expert Aaron Keenan founded Sonex Health in 2014. Sonex Health has developed UltraGuideCTR™ with Meerkat Technology™ to treat carpal tunnel syndrome through a less invasive approach while using real-time ultrasound guidance. Carpal Tunnel Release with UltraGuideCTR and real-time ultrasound guidance allows a procedure that once took place in an operating room to be safely and effectively performed in a surgery center or office setting, resulting in rapid patient recovery, improved cosmesis, and reduced costs. ABOUT UltraGuideCTR The low profile UltraGuideCTR™ with Meerkat Technology™ enables physicians to perform Carpal Tunnel Release surgery through a small wrist incision under real-time ultrasound guidance. CTR with ultrasound guidance relieves the symptoms of carpal tunnel syndrome while minimizing recovery time. Most patients can return to work and the activities in 3-6 days while enjoying immediate motion so they can focus on getting back to their lives and the activities they love. ABOUT UltraGuideTFR Performing trigger finger release with UltraGuideTFR and real-time ultrasound guidance allows for concurrent visualization of the internal structures of the palm and fingers. The ability to identify key anatomical landmarks via ultrasound supports a safe and successful transection of the pulley through a single small incision.

Sonomotion is a medical device startup developing non-invasive solutions for the treatment of kidney stones. The company's stone repositioning and fragmentation solutions are currently in clinical trials in the U.S. and Canada.

Sooma Oy is developing, manufacturing and marketing a non-invasive therapy devices for neurological and psychiatric disorders (depression and chronic pain). Sooma uses transcranial direct current stimulation (tDCS) technology. Our technology is trusted by over 150 clinics worldwide. We feel that everyone deserves high quality care. With our Sooma therapies, we want to provide an effective and safe way to treat disorders within psychiatry and neurology. We want to offer a safe, drug-free treatment option with minimal side effects, that minimises any discomfort that might otherwise come with treating certain disorders. We want to ensure that medical professionals have access to a treatment option for patients which relieves symptoms without any fear of addiction or dependency. Our mission is to make our therapies an available and accessible option for all who may benefit from them. This includes patients who are unable to visit a clinic, but would benefit from a home-based treatment that does not compromise safety. Our first product is the first portable device approved for treatment of major depressive disorder (MDD). The device is CE-approved and currently marketed in the EU and other markets. Our quality management system has been awarded with ISO 13485:2016 and MDSAP certificates.

Spiderwortisdeveloping a novel biomaterial that will offer new avenues in 3D in vitro research and in regenerative medicineusing plant derived cellulose to create a variety of scaffold architectures.

STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLA's first patient subgroup-matched precision treatment. Substance Use Disorder research: STALICLA is working in partnership with the National Institute of Drug Abuse (NIDA) to advance Phase 3 clinical trials for the most clinically advanced drug candidate for cocaine abuse disorder, STP7. STALICLA is now raising series C funding to advance both verticals. For more information visit: https://stalicla.com.

Stempeutics is a leading Regenerative Medicine company in Bangalore with our patented stem-cell therapy platform technology developing treatment of cardiovascular, immune-mediated and degenerative diseases. The company's flagship product, Stempeucel® has received market authorization to treat Critical Limb Ischemia – a major unmet medical need in India. It is the FIRST innovative cell therapy based product to get marketing approval in India and Globally. CIPLA, the Indian licensee, has commenced pan-India commercialization. It has the FIRST DCGI approved Cell therapy product for Knee Osteoarthritis being marketed by Alkem. Stempeutics has a product in the Phase 3 stage covering Diabetic Foot Ulcer. Further it is conducting Phase 2 trial in Perianal fistula due to Crohn’s disease. Stempeucel® has strong patent protection with 20 patents granted including US, Europe and Japan. Stempeucel® has been classified as an Advanced Therapy Medicinal Product (ATMP) and designated as an Orphan Drug for the treatment of CLI due to Buerger’s Disease by the European Medicines Agency (EMA) Another portfolio developed by Stempeutics is Stempeucare® range of cosmetics. It is developed from the stem cell derived Growth Factors/Cytokines combination for various cosmetic and derma applications including rejuvenation of aging skin, hair fall control & hair growth promotion, under eye dark circle reduction cream etc. First product which has gone to the market is an intensive firming skin care cosmetic product, branded as Cutisera™. Other products ready for marketing are Trichosera™ for Hair application and Optisera™ for under eye application With a strong pipeline in Cell and Gene therapy products in some of the largest health and personal care segments like OTC Cosmetics (Skin and Hair Care), Osteoarthritis, Diabetes, CLI and PAF Stempeutics is poised to transform the Cell & Gene therapy space with its India First, Global Next approach.

Stimdia Medical, Inc., is a privately held company headquartered in Minneapolis, MN and has developed the pdSTIMTM System, a minimally invasive, temporary, neuromuscular stimulation system which has received FDA Breakthrough Device Designation. Mechanical ventilation (MV) is considered to be a lifesaving treatment in patients suffering respiratory failure to achieve sufficient pulmonary gas exchange. However, prolonged MV can promote atrophy and contractile dysfunction of the primary muscle utilized in respiration, the diaphragm. Significant loss in muscle mass results in a reduction in diaphragmatic function and compromises the ability of patients to breath on their own. The pdSTIM System was designed to awaken and restore the integrity of the diaphragm muscle in patients who are on MV. This is accomplished with the use of subcutaneously inserted temporary leads connected to the pdSTIM console and utilizes the proprietary RespiSyncTM sensing and stimulation algorithms to coordinate phrenic nerve stimulation with physiologic diaphragmatic movement in synchrony with mechanical ventilators. The pdSTIM System has not yet received regulatory clearances or approvals and is not currently for sale in any country.

Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in psychiatry and neurology, oncology, urology, women’s health, rare disease, and cell and gene therapies. SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliate companies including Sunovion Pharmaceuticals, Inc., Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc. and Enzyvant Therapeutics, Inc. SMPA is a Sumitomo Pharma company.

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is a prominent global pharmaceutical company based in India. Established in 1983, it has grown to become the largest pharmaceutical company in India and the fifth-largest specialty generic pharmaceutical company worldwide. Sun Pharma specializes in generic and specialty pharmaceuticals, focusing on chronic therapies in areas such as cardiology, psychiatry, neurology, gastroenterology, and oncology. The company operates in over 100 countries, with significant markets in the U.S., India, and emerging economies. Sun Pharma produces a diverse range of off-patent generic drugs, including tablets, capsules, injectables, and topical formulations. It also develops complex generics and specialty products for various conditions. The company has a strong commitment to research and development, investing in novel drug delivery systems and biosimilars. With 43 manufacturing facilities across five continents and a workforce of over 37,000, Sun Pharma continues to expand its global footprint and enhance its product offerings.

We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 25 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States. We market Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Supira Medical, Inc. is a portfolio company of Shifamed, LLC., a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements.

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2022, our revenue amounted to SEK 18.8 billion.

Synapse Biomedical Inc (SBI) was founded in September 2002 to commercialize the NeuRx Diaphragm Pacing System (DPS)® that has been developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland. The innovative research performed at these institutions has led to significant advances in the state of the art of electrical stimulation for the treatment of chronic respiratory insufficiency. This innovation allows the technology to meet clinical needs, beyond the ability of the currently available systems, in Spinal Cord Injuries, in the diaphragm conditioning in muscular dystrophies (such as ALS) and in respiratory short-term intensive care settings.

At Synaptrix, we are pioneering accessible technologies to empower individuals with paralysis to live more independently. Our first device, Neuralis™, is a non-invasive, EEG based neural interface that allows paralyzed individuals to control the wheelchair they already use with their brain activity and eye movements. By interpreting signals from visual cortex, Neuralis™ enables intuitive and effortless wheelchair navigation. Neuralis™ is specially designed to meet the needs of paralyzed patients with conditions like ALS, spinal cord injury, MS, strokes, and other neurodegenerative conditions. It provides an affordable alternative to complex, expensive solutions that are often impractical for daily independence. At Synaptrix, we are committed to improving the quality of life for individuals with physical limitations. Through our research, we seek to contribute to the advancement of assistive technologies for patients with neurological conditions, emphasizing the importance of regaining autonomy and control over their lives.

A forward-thinking, medical technology company dedicated to developing life-saving products and therapies that encourage healing, reduce complications of tissue damage and inflammation, prevent infection by drug-resistant bacteria and remove the biofilms in which they thrive. We use the best of nature to solve important, real-time problems.

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. To learn more about the development status of these product candidates, please visit our website at www.talphera.com.

Tasso is a fast-growing Seattle-based startup focused on delivering at-home diagnostic testing to those who need it most. We are growing our footprint with leading health systems, clinical research organizations, academic medical centers, and more who are looking to deliver clinical-grade, convenient diagnostic tests to their patients. Tasso was originally founded to find a better way to collect blood instead of a painful fingerstick or time-consuming venous draw. Since then, our products have been used in pharmaceutical clinical trials, by Olympians as part of a new virtual anti-doping program, and broadly by hospital systems across the US.

Was established in 1993 and is headquartered in the core area of ​​the Eastern Smart City of Guangzhou, covering an area of ​​50,000 square meters. It is the world's leading bioprotein biopharmaceutical company, focusing on the sales and development of biopharmaceuticals in the field of critical illness. and production. The company adheres to the core values ​​of "integrity, integrity; passion, perseverance; commitment, efficiency; care, participation; innovation, learning; cooperation, communication", and owns the national Class II new drug (domestic exclusive variety) Templuoan® (urinol for injection) The company has the exclusive distribution rights in mainland China for the world's first Class 1 new drug Kailikan® (Eurexalin for injection), and the first-line drug Bonroli (ibandronic acid injection) in the field of tumor bone metastasis treatment.

Tempo Therapeutics is a biotechnology company that specializes in tissue engineering using proprietary MAP material science technology to build functional tissue and organs within patients in real time for disease treatment.

Since 2011, Tenex Health has pioneered minimally invasive relief for chronic tendon pain with a one-time ultrasonic treatment. Since 2012, more than 100,000 procedures using the Tenex Health TX technology have been performed. The device is designed for the removal of diseased soft and hard tissue and restoration of healthy musculoskeletal function. Our mission is to provide patients who suffer from chronic tendon pain with a minimally invasive solution to remove the cause of their suffering and get them back to the things they love and need to do with less downtime than traditional treatment methods or surgery. Using conventional ultrasound guidance and the breakthrough Tenex Health TX System, surgeons can quickly and precisely treat only the damaged tendon tissue, leaving the surrounding healthy tendon unharmed. Because the procedure uses ultrasonic energy applied with the TX MicroTip and typically no stitches or general anesthesia are required, there is minimal downtime. Individual results may vary. For more information, visit www.TenexHealth.com.

Delivering the latest innovation in sacroiliac joint surgical solutions, Tenon Medical is uniquely positioned to introduce a refined surgical option for patients with chronic sacroiliac joint pain that fail conservative care. The Catamaran™ SIJ Fusion System offers a patented new surgical solution that places a single implant directly into the SI joint. Tenon Medical is led by a powerful team with years of cumulative experience in designing and launching innovative surgical solutions that deliver a pathway to improved quality of life for thousands of patients.

Thrombolex is engaged in the design, development, and distribution of innovative endovascular catheters used in interventional procedures, particularly in pharmaco-mechanical catheter-directed thrombolysis (PM-CDT) in patients who suffer from arterial and venous thromboembolic (A&VTE) conditions. The Company is currently marketing seven (7) different FDA-cleared devices that are all based on the BASHIR™ Endovascular Catheter platform technology.

Although our primary product is high-quality human amniotic tissue grafts, we are really in the business of helping people. Tides Medical® sources and acquires donated placentas to make advanced skin substitutes available to the patients who need them. Then we work with physicians and their staff to help them navigate the complex reimbursement process. Our goal in providing these advanced products and expert service is that we will remove the barriers that might prevent patients from accessing the full range of treatment options they deserve. It’s a challenge that our team takes personally.

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®'​) technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care. In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.'​, rebranded 'TRX BioSurgery'​ in February 2018. January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany. In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

Tolmar is a Northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. Tolmar develops and manufactures both proprietary and generic pharmaceutical products with specific focus in dermatology, oncology, and specialty injectable therapeutic areas.

TransMedics was founded to address the growing need for healthier organs for transplantation. We are focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs. The Organ Care System (OCS™) platform is a revolutionary technology for preserving organs used in the treatment of end-stage heart, lung, and liver failure. The OCS is the first and only multi-organ platform to leverage proprietary core technologies across multiple organs.

Transplant Genomics is a biotechnology company that focuses on improving organ transplant outcomes through noninvasive serial monitoring driven by genomics.

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans1, of which Treace estimates 1.1 million are annual surgical candidates. Treace Medical has pioneered and patented the Lapiplasty® 3D Bunion Correction® system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause2,3 of the bunion. At Treace Medical Concepts, Inc., our mission is to advance the standard of care for the surgical management of bunions and related midfoot deformities. Treace Medical offers the Adductoplasty® System, the Hammertoe PEEK Fixation System, the SpeedPlate™ System, and other ancillary The content herein is for informational purposes and intended for healthcare professionals only. Treace Medical Concepts, Inc. does not dispense medical advice. A surgeon should rely on his or her own professional clinical judgment when deciding whether to use a specific product when treating a particular patient. Prior to use of the device, the surgeon should refer to the instructions for use for complete indications, contraindications, warnings, and risks. Complete risk and benefit information: www.treace.com. Visit www.treace.com/privacy-policy for our Privacy Policy. Treace Medical will make an offer of employment only to individuals who have applied for a position using our official application. Be on alert for possible fraudulent offers of employment. Treace Medical will not solicit money or banking information from applicants. 1Nix S, et al. J Foot Ankle Res. 2010. 27:3:21. 2Dayton P, et al. J Foot Ankle Surg. 2016;55:567-71. 3Dayton P, et al. J Foot Ankle Surg. 2018;57:766-770.

TRiCares GmbH is a medical device company based in Munich, Germany, with additional offices in Paris, the U.S., and Brazil. Founded in 2013, the company specializes in minimally invasive solutions for tricuspid regurgitation (TR), a serious heart valve condition affecting millions of patients. TRiCares focuses on transcatheter tricuspid valve replacement (TTVR) systems, aiming to meet the clinical need for non-surgical treatments. The flagship product, Topaz, is a transfemoral TTVR system designed for easy implantation via the femoral vein. It features a dual-stent design that accommodates anatomical variability and is suitable for high-risk patients, avoiding the need for open-heart surgery. TRiCares is actively conducting clinical trials in the U.S., Canada, and Europe to further validate the effectiveness of the Topaz system. Recently, the company raised $50 million in Series D financing to support its clinical milestones and expand its market presence.

Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than 150 U.S. and International patents including applications. We market several branded and generic products in the U.S; license our products in the U.S. and international markets and we have a robust pipeline of innovative products, that employ our proprietary science and technology, to meet patients' needs in neuroscience and other therapeutic categories. Our science and technology make us unique, but it is our team members that set us apart; they are the engine that fuels Tris' passion and innovation. The Tris team comprises of approximately 500 diverse individuals; one third of whom operate in the field throughout the U.S. while the other two-thirds work from Tris' NJ operations. Tris colleagues understand the criticality of operating a successful business and take pride in the company's success. But of equal importance to each member of the team is how we interact with one another on a daily basis. We believe in each other and we believe in respectful, open and honest communications to help support individual and team success. At Tris we strive to ensure our field and home office teams are connected and engaged. We listen to our teams in numerous ways including through our Diversity & Inclusion Committee and our Women's Business Council to help to ensure every employee's voice is heard. After all, it is our daily interactions with one another that build and sustain our culture which fuels our growth.

TRPHARM’s journey, which started in Turkey in 2013, continues with offices in Istanbul and Dubai. Currently, we deliver our products and services to approximately 20 countries, and we maintain our physical presence in 12 of these countries. We are growing rapidly with more than 100 employees who are competent in their fields. We combine our innovative business approaches with medical experience, with the experience of more than a hundred years of experience of the doctors and pharmacists in our team. Our journey that started with medicine continues with the inclusion of non-pharmaceutical health solutions. With our partners in various countries, we provide a wide range of services covering all areas from diagnosis to treatment. Our cooperation philosophy is based on transparency and coexistence within the framework of common goals, guided by our expertise. As TRPHARM, our mission that we have been loyal to since the first day is to bring together innovative solutions with health. Our vision, which we have created with our years of experience, is to be a global, innovative healthcare company. The values that we take as a guide in each of our steps are; LIFE We put people and nature at the heart of our relations with our colleagues, physicians, patients and all other stakeholders and aspire to build a sustainable ecosystem. COLLABORATION In all our actions and business activities, we put harmony, unity and efficiency at the center of our interactions and projects, both within our teams and with our stakeholders. BALANCE In all areas that we add value, we draw on broad vision and harmony of opposite poles/perspectives, and we observe balance and attentiveness in our actions. TRANSFORMATION We adapt to ever-changing conditions that life imposes on us all with resilience and courage. We foresee transformation and changes in needs, respond with agility and grasp new opportunities to achieve our leadership goal.

UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With approximately 9000 employees in around 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2023 Key Financials: € 5.3 billion global revenue Specialties: Neurology, Immunology

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.

Uptake Medical® developed innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor®, was the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any foreign materials in the lung. Uptake Medical was acquired in July 2016 by Uptake Medical Technology Inc, a subsidiary of Broncus Holding Corp.

Valencia Technologies is a neuromodulation company transforming the standard of care for bladder dysfunction. The coin-sized electroceutical - eCoin® - is a radically small neurostimulator that automatically provides safe and effective treatment for Urge Urinary Incontinence. It has the experienced leadership of Jeff Greiner and the talented team to bring this platform medical device to market for the treatment of various chronic conditions. The company arose from the discovery that more scientifically verifiable work was being done in acupuncture and that there was a place for neuromodulation to further advance the work. Valencia designed and developed the eCoin® for the treatment of major chronic conditions. Engineered and designed by Dave Peterson and Chula Thenuwara, the eCoin® is unique as a leadless device that is 1/8th the size of the smallest pacemaker-like device on the market. For more information on Valencia and the current offering, please visit our website at www.valenciatechnologies.com

Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

Vapotherm, Inc. is the inventor of high flow nasal cannula, and its advanced form: Vapotherm high velocity therapy. Delivering high velocity therapy, the Precision Flow® system offers clinicians a reliable tool for multiple patient populations. For respiratory distress patients presenting in the ED and ICU, high velocity therapy can provide not just oxygenation, but also Mask-Free respiratory support with the comfort of heated humidified high flow. Vapotherm, Inc. is a publicly traded company and its common stock trades on the OTCQX tier of the OTC Markets under the symbol "VAPO".

Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients. Headquartered in Cary, North Carolina, USA, Veloxis is focused on the global development and commercialization of medications utilized by transplant patients and by patients with serious related diseases. We know what transplant means to patients, and we’re leading innovation to improve their experience. For patients, transplant is a life-changing procedure. But changes come with challenges. At Veloxis, our mission is to see and respond to the challenges along the transplant journey.

Venus Medtech is a prominent player in transcatheter technologies for structural heart disease therapies. Our comprehensive solutions treat all four heart valves within the human heart (TAVR, TPVR, TMVR, TTVR) in addition to hypertrophic cardiomyopathy, hypertensive renal denervation therapy. Founded in 2009 and headquartered in Hangzhou National High-Tech Industrial Development Zone (Binjiang), the company successfully listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2500.HK) in December 2019. Our journey began with the launch of our first product in 2014, under the New Bioprosthetic Aortic Valve Project in China. We followed this with the introduction of the VenusP-Valve in Europe in 2022. We partner with the top physicians across every continent to understand their challenges and identify opportunities. These insights drive novel breakthrough solutions for a better tomorrow. We invest more than $200M in R&D every year, operate in more than 650 centers worldwide, hold a portfolio of more than 800 patents, and boast a track record of more than 13,000 real-world implantations. As a global leader in the making, Venus Medtech's strategic focus is and will always remain to pioneer innovative technology and equip physicians with the tools they need to enhance the quality of life for patients worldwide.

From discovery to scale, Verb Biotics applies science, technology, and intentional development to deliver microbiome health solutions. Verb Biotics is a business-to-business ingredient supplier of pro, post, and synbiotics for food, beverage, and dietary supplement brands.

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.twitter.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Vifor Pharma is a Switzerland-based pharmaceutical company that develops nephrology and cardio-renal therapies for the treatment of heart failure and kidney diseases.

Volumina Medical is a multi-award-winning start-up active in the field of medical devices supported by a solid network of investors. The company develops breakthrough innovations for plastic and reconstructive surgery. The first product is an implantable polymeric biomaterial and targets the regeneration of soft tissue of the human body which are damaged after tumor excision, genetic malformation or trauma.

V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with chronic Heart Failure (HF). As a leading cause of death and hospitalization, HF continues to affect millions of people worldwide. V-Wave's vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company's senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices.

Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue. www.xeltis.com

Minimally Invasive Technology for Obstructive Sleep Apnea

Yuhan Corporation is an integrated healthcare company founded in 1926. It has achieved top market value and sales revenue in Korean pharmaceutical industries, and been awarded for the most respected and trusted company in Korea for recent 11 consecutive years. It has two subsidiaries, Yuhan Chemical and Yuhan Medica, and the affiliates including Joint Ventures with Janssen(Belgium), the Clorox Company(USA), and Kimbery-Clark Corporation(USA). The core business of Yuhan can be classified into Primary & Specialty care, Dietary supplement, Household & Animal care, and contract manufacturing of active pharmaceutical ingredients.

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We advance our mission to alleviate pain and improve the quality of life for patients around the world with our innovative products and suite of integrated digital and robotic technologies leverage data, data analytics and artificial intelligence. Founded in 1927 and based in Warsaw, Zimmer Biomet has operations in more than 25 countries and sales in more than 100 countries. We maintain world-class scientific facilities and resources and collaborate with leading clinicians and researchers around the world. Awards and Recognitions • Forbes Best-in-State Employers in Indiana (2020 and 2021) • Newsweek's America's Most Responsible Companies (2021) • Military Friendly Employer by VIQTORY (2019 and 2020) • Best Employer Award: China (2011-2021) • Great Place to Work: Brazil (2021) • Indiana Manufacturers Association Manufacturing Excellence Awards (2020) • ComputerWorld's "Best Places to Work in IT" (2018-2020) • Forbes Global 2000 (2020 and 2021) • Fortune 500 List (2020 and 2021) • Medical Device and Diagnostic Industry MedTech Company of the Year (2019)